When working towards an optimised Carotid stenting procedure does patient, procedural and pharmacological selection impact on outcome. by Randall, Marc
 
 
 
 
 
 
Access to Electronic Thesis 
 
 
Author: Marc Randall 
Thesis title:    When working towards an optimised Carotid stenting procedure does 
patient, procedural and pharmacological selection impact on outcome. 
Qualification: MD 
Date awarded: 29 July 2010 
 
 
This electronic thesis is protected by the Copyright, Designs and Patents Act 1988.  
No reproduction is permitted without consent of the author.  It is also protected by 
the Creative Commons Licence allowing Attributions-Non-commercial-No 
derivatives. 
 
 
This thesis was embargoed until 31 May 2011 
 
 
 
If this electronic thesis has been edited by the author it will be indicated as such on the 
title page and in the text. 
 
 
 
 
 
 0   
 
 
 
 
 
 
 
When working towards an optimised Carotid stenting procedure 
does patient, procedural and pharmacological selection impact on 
outcome.  
 
 
Dr Marc Stewart Randall 
 
MD Thesis 
 
Department of Genomic Medicine (Academic Neurology) 
 
January 2010 
 
 1 
 
  
Acknowledgements 
 
I would like to thank my supervisors Prof. Graham Venables and Prof. Peter Gaines for 
their invaluable assistance and guidance throughout this project.  I also would like to 
acknowledge the assistance from Dr Trevor Cleveland and Dr Robert Storey who 
helped with many parts of the project.  I also wish to acknowledge the stroke research 
nurses particularly Keith Endean who have assisted in collecting data and maintaining 
the ongoing departmental stroke databases. 
 
I reserve a special mention of gratitude to my wife Helen, my sons William and James 
and my parents Tony and Diana as without their support this thesis would not have been 
completed. 
  
 2   
Abstract 
 
Carotid intervention for stroke prevention in the form of carotid artery stenting has been 
performed in clinical trials since the beginning of the 1980’s.  Improvements in the 
operative technique and pharmacology used during the procedure have reduced 
complication rates since stenting began.  Long term follow up of the Sheffield data set 
has shown that patient selection has the most impact on reducing adverse outcomes 
from the procedure.   
 
Multivariable analysis of the Sheffield database detailed in this thesis has shown that 
retinal events have a lower risk of adverse outcomes than cerebral events, and 
clopidogrel use at the time of stenting prevents adverse events.  Recurrent stenosis of 
more than 50% also increases risk for recurrent stroke in the long term and therefore 
warrants a long term surveillance programmes in stented patients.  It was possible to 
show from the same analysis that stenting patients as a routine procedure prior to 
cardiac surgery had no immediate benefit in reducing operative stroke risk from the 
procedure. 
 
The EPICAS study was developed from these initial observations to investigate the 
effects of variability in response to clopidogrel on outcomes.  Using transcranial 
Doppler detected embolic events as a clinical endpoint for comparison with the 
clopidogrel dependant pathways of platelet activation the study hoped to show a direct 
effect of the degree of platelet inhibition on the number of emboli detected.  This was 
not shown to be the case in the patients studied as part of this work.  Patients classified 
as non responders to clopidogrel had no difference in emboli counts before and after the 
stenting procedure (p = 0.24).  The results suggest that a variance in response to 
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clopidogrel is unlikely to be clinically significant even in larger cohorts of patients.
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Summary 
 
Carotid angioplasty and stenting to treat carotid artery stenosis in symptomatic and 
asymptomatic patients has been developed by vascular interventionalists from the early 
1980’s as an alternative technique to the proven benefits of carotid endarterectomy.  The 
Sheffield Vascular Institute and Department of Neurology were one of the earliest 
adoptees of angioplasty and stenting of the carotid artery in the UK and have adapted 
and studied the technique since inception.  Much of this work has been published by the 
department.
1-7
  However, despite extensive research in the field of carotid stenting the 
procedure continues to have a stroke risk of between 3 % and 5 %.  This thesis 
represents continued work to improve the safety of the procedure using an extended 
multivariate analysis of previously unpublished 30 day and long term outcomes in 
symptomatic stenting, a cohort analysis into the benefits of asymptomatic intervention 
prior to cardiac surgery, and a detailed experimental assessment of the impact of 
clopidogrel resistance during carotid stenting. 
 
Several of the randomised trials comparing carotid endarterectomy and carotid stenting 
have now published 30 day outcomes that were not available at the start of this period 
of research.  Recruitment and randomisation into these trials has been performed over 
many years during which the procedure of carotid stenting has been developed.  These 
changes have included the routine implementation of additional medical therapies, 
developments of device characteristics and the additional perceived impact of an 
operator learning curve in the stenting arm of these trials.  A multivariate analysis of the 
Sheffield stenting database was conceived as an initial screen to detect elements 
impacting on outcomes in the Sheffield patients, and the preliminary analysis was 
presented at the world congress of neurology in 2005.  An analysis of this sort has not 
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previously been undertaken in an entirely symptomatic group of patients.  The 
maintained and modified analysis of the data is presented in its most recent form in 
chapter 2. 
 
The Sheffield Vascular Institute has also served as a quaternary referral centre for 
carotid stenting procedures prior to coronary artery bypass grafting or valve 
replacement.  This procedure has become a common request from cardiothoracic 
surgeons in patients who have bilateral high grade carotid artery stenosis.  The 
theoretical benefits of performing a staged carotid stent prior to cardiothoracic surgery 
were felt to reduce peri operative stroke or death risk.  In a review of the Sheffield 
carotid stenting procedure to improve its overall safety the optimising selection of 
patients was of interest, and if no benefit could be shown from the combined approach 
then stenting these patients posed unnecessary risk.  The analysis published 
8
 and 
detailed in chapter 3 was performed to fill a void in the literature for the overall efficacy 
of the combined procedures.  The safety and clinical benefit of this combined approach 
remains in question today. 
 
The first randomised study of the benefits of combined antiplatelet therapy in carotid 
stenting using clopidogrel and aspirin was performed in a cohort of Sheffield patients by 
researchers from the department on neurology.  The outcomes of this study were 
analysed and published during the planning stages for the EPICAS study and showed a 
clear benefit for combined antiplatelet therapy.
9
  The risk of stroke or adverse event in 
patients treated without clopidogrel was significantly higher and was confirmed in the 
initial assessments of 30 day outcomes of the stenting database detailed in chapter 2.  
The EPICAS study was undertaken in response to a perceived risk of significant harm 
to patients who were, “clopidogrel resistant.”  Clopidogrel resistance presented a clear 
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clinical risk if up to 20% patients were truly clopidogrel resistant then 20% of all stent 
patients were effectively undergoing carotid stenting without adequate antiplatelet cover 
as suggested by our randomised trial.  Alternative antiplatelet agents have been 
investigated in addition to the combination of clopidogrel and aspirin, but have been 
shown to be too high risk to be used in all patients undergoing carotid stenting.  The 
EPICAS protocol was designed to address this issue by trying to identify if patients 
classified as resistant to clopidogrel on platelet testing had a clinically higher risk of 
peri operative stroke.  This would then allow judicious use of intravenous antiplatelet 
agents in this high risk group in the peri operative period.  The methodology and results 
of this study are detailed in the remaining chapters of this thesis. 
 
The results of the EPICAS study have suggested that the variation in response to 
clopidogrel and its impact on platelet function may not be as significant as we had 
predicted, with the majority of the outcome measures assessed showing no statistically 
significant trends.  The relevance of our findings in the light of more recent research 
from other centres published during this trial is reviewed in the closing chapter.
 10  
1 Introduction 
 
i) Carotid Intervention from Endarterectomy to the birth of Stenting. 
 
This thesis describes work undertaken to improve clinical outcomes from patients 
undergoing carotid artery stenting for secondary stroke prevention in a tertiary teaching 
hospital setting.  The prospectively maintained Sheffield carotid stenting registry has 
been used in conjunction with the ethics approved Effective Platelet Inhibition in 
Carotid Artery Stenting (EPICAS) study to identify specific targets for optimising the 
stenting procedure (www.nrr.nhs.uk ID: N0059132292).  Review of the benefits of 
carotid stenting procedure in “asymptomatic,” patients prior to cardiac surgery was also 
assessed as part of our optimisation of the stenting procedure in our institution. 
 
History of carotid intervention 
 
The clinical relevance of sustained, unimpeded blood flow through the carotid artery 
was first commented on by the physicians of ancient Greece.  Hippocrates (460 to 370 
BC) original descriptive writings of his neurological assessments in patients lead us to 
deduce that he was aware that the, “convulsions and paralysis of the limbs,” he 
described could follow injury to the brain.  What is not clear from the writings of the 
ancient Greeks is if they were aware of exact causation of stroke.  It was not until 
writings by Rufus of Ephesus (98- 117 AD) describing external compression of the 
carotid vessels inducing, “karos,” in certain susceptible individuals that the impact of 
the damage to the carotid artery was realised.  The Greek word karos or karotide 
literally means to stupefy, or plunge into a deep sleep, and it is the derivation of this 
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word now that names these essential blood vessels which form the focus of this thesis.
10, 
11
 
 
Causation of stroke or, “apoplexy,” by atheroma and thrombosis of the carotid arteries 
was discussed by Johann Webfer in 1675 in his work, “Observationes anatomicae, ex 
cadaveribus eorum, quos sustulit apoplexia,” and this is probably when direct causation 
of stroke by internal carotid artery disease was first considered.  However, despite the 
knowledge of causation it did not lead to physicians taking the next step and operating 
on the carotid artery until 1798.  Initial attempts at carotid surgery were simple ligation 
procedures to stem blood flow and save life, invariably following trauma, and often 
with variable degrees of success.
12
  The notion of operating on a diseased artery in a non 
life threatening situation to prevent future ischaemic cerebrovascular events was not 
considered until the publications by Miller Fisher in 1951, and again in 1954 examining 
the relationship between frequency of carotid artery disease and cerebrovascular 
insufficiency.
13, 14
  Routine successful surgery on carotid arteries to treat carotid artery 
stenosis in patients with a history of intermittent cerebral dysfunction and carotid 
disease begins in 1953. 
 
An American surgeon, Michael Ellis De Bakey, carried out the first successful carotid 
endarterectomy whilst head of surgery at the Baylor College of Medicine in Houston.  
The operation was highly successful with his patient making an uneventful post 
operative recovery, and is later described with 19 yrs follow up and no further 
cerebrovascular events until the patients death from coronary artery disease in 1972.
15
  
The original procedure described was novel but applied techniques learned for 
peripheral vascular disease in the carotid arteries.  It was undertaken without any 
preoperative imaging, and was based only direct clinical assessment and an assumption 
 12  
of finding a pathological lesion based on knowledge from previous descriptions of 
stroke and post mortem studies.  Thankfully, in this case the evidence free approach was 
successful and encouraged development of the basic technique still used today in 
surgical carotid intervention.  However, as this case was not reported for several years 
the expansion in carotid surgery that occurred shortly afterwards cannot be attributed to 
it.  The greatest impetus to carotid surgery development was most likely Eastcott’s 
group at St Mary’s Hospital, London in 1954.16  The number of procedures performed 
for, “carotid insufficiency,” then grew exponentially as various groups reported 
successful outcomes from the operations with low self reported mortality figures of 
between 2 % and 3.3%.
17, 18
  Comparative data from the time suggested that untreated 
patients had mortality rates approaching 20%, and therefore surgical intervention was 
considered a favourable option.
19
  Various carotid reconstruction techniques were 
assessed, but the technique of endarterectomy, originally described by Cid Dos Santos
20
 
in peripheral arterial disease, and used by De Bakey became the eventual technique of 
choice. 
 
Operative and post procedural complications will occur, no matter how meticulously the 
operator applies a technique.  The variability in the numbers of adverse clinical 
outcomes due to endarterectomy seen between countries and at different centres within 
individual countries led to questions about the appropriateness of these procedures, and 
lead to the first randomised trial of carotid surgery which was published in 1984 from a 
single UK centre. 
21
  Continued uncertainty surrounded the role for surgical intervention 
and recruitment was slow.  With only small numbers recruited the outcome tended 
failed to support surgical intervention over the limited medical therapies of the time.  
Whilst controversial, in the opinion of some observers, it provided impetus for larger 
randomised trials investigating the benefits of surgical carotid intervention to prevent 
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stroke and TIA over and above the benefits of medical therapies of the time.  
Antiplatelet agents had increasing evidence for a definitive role in treating patients with 
recent stroke and TIA which it was hypothesised negated the benefits of surgery.  
Confirmation of the benefits of antiplatelet therapy in secondary prevention of stroke 
came later with the publication of the two large antiplatelet trials (IST1 and CAST).
22-24
 
 
The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the 
European Carotid Surgery Trial (ECST) collaborative groups on either side of the 
Atlantic developed large randomised trials to confirm the benefits of surgical carotid 
intervention in addition to medical therapies.  The trials initially used differing methods 
to measuring the degree of carotid stenosis in the internal carotid and had slightly 
differing inclusion criteria but both achieved similar outcomes.  Carotid endarterectomy 
was beneficial over and above best medical therapy for significant high grade carotid 
stenosis greater than 70 % when based on the NASCET measuring criteria.
25, 26
  These 
trials have undergone further review in combined meta analysis and the results are 
unchanged.
27
  What has also been demonstrated by the trials is that intervention, while 
remaining beneficial at 6 months after the initial presenting minor stroke or transient 
ischaemic attack (TIA), has greater benefit the sooner the procedure is performed.  
These pivotal trials continue to provide insight into the optimal management of carotid 
arterial disease, including suggesting that the severest stenoses with near or total 
occlusion gain no benefit from surgery.
28
  The trial results have also been shown to be 
reproducible in non selected populations outside of a trial setting.
29
   
 
Interestingly, it was patients with near or complete occlusions that were chosen to be the 
first patients to undergo procedures back in 1953.  The numbers of patients involved in 
these and subsequent carotid intervention trials has ensured that the procedure of carotid 
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intervention is one of the most robust, evidence based, vascular surgical procedures 
performed to date, and the trials involving carotid stenting procedures continue to add to 
this strong evidence basis.
 15 
 
 
Development of Carotid Angioplasty and Stenting. 
 
The procedure of endovascular carotid intervention was proposed in the early 1980’s as 
an alternative to endarterectomy to provide similar stroke prevention benefit, and the 
first carotid angioplasty balloon was used on a common carotid lesion during an open 
endarterectomy.
30
  The development of balloon angioplasty of the neck vessels was 
slow in the first instance due to competition from the robust carotid endarterectomy 
procedure it was being compared to.  The initial angioplasty procedures were not 
performed on atherosclerotic plaques but on critical stenosis of the internal carotid 
arteries in patients with fibro muscular dysplasia,
31, 32
 and vertebral artery origin 
stenosis.
33
  Concerns about cholesterol plaque embolisation were the limiting factors in 
the development and acceptance of the procedure.  With no direct control over distal 
blood flow in the carotid the risk of embolisation was felt to be higher in carotid 
angioplasty.  Therefore, endovascular techniques were used only on lesions felt to be 
non operable by conventional means, either due to their location or a previous failure 
with the endarterectomy technique e.g. Takayasu’s arteritis,34 and subclavian steal.35   
 
The first successful descriptions of angioplasty performed for atherosclerotic lesions 
were published by American authors in 1983,
36, 37
 and a further European group in 
1984.
38
   The procedure of primary transluminal catheter angioplasty (PTCA) was 
chosen in these selected patients as an alternative to endarterectomy due to high surgical 
risk from the medical co morbidities of the patients involved.  Of the eight patients 
described in the three initial reports only one had an immediate post procedure 
neurological complication.  Despite these initial successes in highly selected groups of 
patients the technique remained controversial and was not universally accepted as a 
promising alternative to endarterectomy.  The reluctance to undertake the developing 
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procedure explains why it took a further two years for the European group to perform 8 
procedures in total,
39
 and the first true assessment of the endovascular technique was 
not undertaken until the CAVATAS investigators began randomisation into the 
endarterectomy vs. angioplasty trial for symptomatic atherosclerotic lesions in 1991.
40
 
 
In the absence of a randomised trial several groups continued to perform balloon 
angioplasty in selected cases for atherosclerotic disease outside of a controlled trial 
setting.  In an identical situation to the initial endarterectomy procedures individual 
groups reported complication rates of permanent neurological deficit of between 0% 
and 9.5% and those for transient neurological deficits between 0% and 57%. 
41-45
  
Closer inspection of these figures reveals that between 1986 and 1990 the number of 
patients published in peer reviewed series of endovascular carotid intervention for all 
indications was 59 worldwide,
41-45
  and did not increase until 1991 when a German 
group published their own experience with 38 carotid territory angioplasties and 
reviewed 177 carotid territory angioplasties from the literature.
46
  Combined all 
indication, all cause, complication rates of 1.7% major complications, defined as death 
or permanent disability, and minor complications of 2.3% were quoted by this 
publication, and the data was used by the authors to suggest possible equivalence 
between angioplasty and endarterectomy.  This claim met with considerable opposition 
from vascular surgeons.  Publication bias clearly has a significant influence on the 
number and type of outcomes in case series dramatically skewing the data in these small 
numbers so it became an unreliable indicator of the true safety profile of these initial 
procedures.   
 
The CAVATAS trial began in 1992 to prove equivalence of endovascular intervention 
with endarterectomy.  Interim results were published in 1996 and 1999, but its long 
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term follow up was not complete and published until 2001.
40
  The vacuum of 
knowledge throughout the 1990’s was supplemented with data from short case series, 
individual patient reports and small single centre studies.  Results from these 
publications supported continued use of the procedure in selected high risk patients 
outside of a randomised trial when carotid endarterectomy was not an option.
47
  
However, these studies lacked the independent neurological assessment which the 
CAVATAS trial design allowed for, and has since been postulated to have resulted in a 
more accurate determination of the true neurological complication rates of these 
procedures’.   
 
The first data from CAVATAS trial patients was published in 1996 when 193 patients 
had been randomised.
6
  At the same time other groups in Europe and America were 
publishing larger, self reported, single centre, non randomised case series, with good 
clinical outcomes.
48-51
  What is important to note, and relevant to the design of the 
research on which this thesis and the EPICAS study is based, is how rapidly the 
angioplasty procedure was changing even within the few months that these publications 
were released over.  Of particular interest is the dramatically differing procedural 
methodology especially in the use of anti-thrombotic measures by different clinicians.  
The technique of carotid angioplasty and stenting was being developed with no clear 
consensus on an optimal treatment approach.  Rapidly changing technology and the lack 
of a unified technique requires historical literature to be reviewed critically to determine 
the impact any of these procedural modifications may have had on outcome.  Several 
modifications to the stenting technique when critically assessed have a limited evidence 
basis, and therefore when designing a trial investigating the role of platelet agents these 
factors need to be taken into account. Published examples of differing practice serve to 
highlight this.   
 18  
 
The CAVATAS data published in 1996 was comprised mainly of simple balloon 
angioplasty procedures with occasional stent placements using modified non carotid 
stents as permitted in the trial protocol from 1994 onwards.  Two American series 
published at the same time used stents for the majority of their patients.  Patients from 
the CAVATAS group all received heparin for 48 hours post procedure in addition to an 
oral aspirin loading dose of 300mg.  In contrast one American group gave no post 
operative heparin relying solely on Aspirin to prevent thrombotic events,
48
 another 
American group and a European group routinely used Ticlopidine in place of Aspirin in 
patients undergoing angioplasty,
49, 50
 and a French group reported the use of routine 
Ticlopidine and subcutaneous heparin as an anti-thrombotic in all patients receiving 
stents.
51
  This variability in technique prevents combined analysis of the data from the 
initial angioplasty procedures to be undertaken with any meaningful results, and the 
multivariate cohort analysis detailed in this thesis was designed to address some of these 
issues.
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ii) Optimising carotid stenting the drive to modify the technique. 
 
Achieving adequate cerebral protection became the driving force behind rapid changes 
in the methods used for endovascular carotid intervention.  Fears surrounding the safety 
of balloon angioplasty had focused on the risk of distal embolisation into the cerebral 
circulation from cholesterol crystals, plaque debris and platelet aggregations derived 
from the carotid plaque under treatment.
52, 53
  The type, and size, of embolic material 
has been shown to be closely related to the stage of the angioplasty procedure being 
undertaken,
54
 and operators began modifying their practice to reduce the risk of embolic 
complications occurring at each of these stages.  Developments in stenting technology 
provided single wire delivery systems and low profile dilatation balloons to reduce the 
risk of dislodging embolic material from numerous wire changes passing through the 
offending lesion, and protection devices were developed to catch debris. 
 
Surgeons undertaking carotid endarterectomy have the benefit of being able to reduce 
cerebral embolic load by clamping distal to the lesion, or by shunting to bypass the 
operative field and protect the brain from distal embolisation.  Initial therapeutic 
adaptations focussed on a perceived requirement for distal protection during carotid 
angioplasty and stenting and distal balloon occlusion devices discussed in Theron’s 
paper in 1987
44
 were the first modifications adopted by some interventional 
radiologists.  His ideas were universally adopted by most other operators who 
developed the technique and catheters to suit their methods.
55
  Although a good idea in 
theory the use of these devices was never subject to a randomised study before universal 
implementation.  Methods then focussed on three protection techniques including distal 
balloon protection, proximal flow occlusion and flow reversal.
56-60
  Theron’s large 
series published in 1996 made a strong case for routine cerebral protection with his 
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distal protection technique having no embolic complications among the 136 patients he 
treated despite there being no control arm in his series.
51, 61
  The benefits of cerebral 
protection devices were finally given limited scientific justification when a randomised 
trial was published in the late 1990’s.62  This trial had been stopped early due to a 
significant number of adverse events in the stenting arm which had failed to use cerebral 
protection devices.  However, even the balloon protection devices, which have been 
shown to be highly efficient at collecting debris from the procedure, are not able to 
reduce intra-operative complications entirely due to incomplete collection of all 
particulate matter.
63, 64
  In most series peri-operative complication rates with balloon 
occlusion devices are between 1.6% and 2.3%.
65, 66
  These occlusion devices are also 
limited by the requirement to have a functioning circle of Willis to avoid cerebral hypo 
perfusion complications during device inflation.
67
 
 
As an alternative to balloon occlusion filter devices were developed to capture 
particulate debris from the carotid artery preventing stroke.  Initial in vitro experimental 
studies suggested that they may be at least 80% efficient in stopping all particulate 
matter from the procedure.
68
  Initial experiences published as case series suggested the 
filters were highly effective with intra-operative complication rates of 0% and 1.2% 
encouraged widespread use of the devices.
69-71
  A recently published follow up of these 
devices in regular use has confirmed these operative complication rates can be 
maintained, and has shown no statistically significant difference between the design and 
type of device used.
71
  However, the increasing use of these filter devices in routine 
practice has required optimisation of intra procedural antiplatelet and antithrombotic 
therapies to prevent filter clotting while the filters are in place and may add to bleeding 
risk.
72
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Only one true randomised trial of protection verses no protection has been carried out 
and this is sub set analysis of an ongoing trial not yet published.   Trials who have 
recruited patients early in the development of stenting when protection use was not 
widespread and historical analysis of registry data of patients treated with and without 
protection is the only clinical data of the true benefit of these technologies we have 
available to us.  One of the largest of these registry studies confirmed a significant 
difference between the protected (0.9%) and unprotected groups (2.3%) but this 
difference was statistically insignificant (p= 0.15), due to the small numbers of 
unprotected patients.
71
   In one study the complication rates for major stroke were 0% in 
both protected and unprotected groups and the rates for minor stroke were 3.2% 
unprotected vs. 0.7% protected. 
73
  Other large series have stroke and death rates of 
1.1% and all complication rates of 3.4%.
74
  A systematic review of all cases published 
in the literature shows rates for the outcome of all stroke and death to be 5.5% 
unprotected vs. 1.8% protected.
75
  This observational evidence prevented proper 
randomised studies being undertaken and changes to the protocols for the trials of 
endarterectomy vs. stenting studies make this unlikely in the future. The 
Endarterectomy Versus Angioplasty in patients with Symptomatic Severe carotid 
Stenosis (EVA-3S) trial for example was modified to prevent patients having CAS 
performed without protection due to abnormally high complication rates in procedures 
performed without a protection device in place.
76
   
 
No protection option can provide one hundred percent protection from embolic events, 
clinical strokes and transient ischemic attacks still occur with their use but less 
frequently and when they do occur are often after the initial operative period.  Magnetic 
Resonance Imaging (MRI) studies have confirmed the presence of clinically silent 
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ischaemic events on diffusion weighted imaging occurring after the stenting procedure 
has been completed.
77, 78
 
 
These changes have been seen in cases with and without cerebral protection 
79, 80
 and 
could represent events occurring after the protection device has been removed and 
therefore the role of the protection device in preventing these silent events is difficult to 
ascertain.
81-83
  One method to optimise the degree of cerebral protection offered in 
particular to patients, with poor collateral flow via the circle of Willis has been to use 
two protection devices in tandem in a, “seat belt and airbag,” approach.84  Analysis of 
the Sheffield data in this thesis failed to provide clarification for a role of the protection 
device in routine use. 
 
Implementing the routine use of stents, already shown to be efficacious in the coronary 
arteries, was the next logical step in controlling complications.  The first experimental 
use of stents in animals was performed in 1987 with three carotid stents successfully 
inserted.
85
  The first human use of stents in the carotid artery was reported in 1994 in 
two patients who had suffered carotid dissection and a further case in an Italian 
patient.
86, 87
  The first reports of stenting atherosclerotic lesions in 1996 used Palmaz 
biliary stents adapted for use in the carotid circulation.
88, 89
  Initial successes with lower 
post operative complication rates using these non specialised stents was supported by 
prospective non randomised studies into 30 day neurological outcomes with their use. 
The effect on 30 day outcomes was likely due to the lower embolic potential of stent 
insertion when compared to angioplasty, and was later confirmed in experiments 
performed on human cadavers 2 years after their initial routine use in patients.
90
  
Imaging follow up of these successful stent procedures demonstrated that some stent 
designs deformed when used in carotid vessels and in particular the Palmaz stent was 
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withdrawn from use.  This was replaced by the self expanding Wallstent in the majority 
of the remaining patients in early published series.
50, 91
  Cases of deformed carotid stents 
continued in the literature into 1998 and in addition to the Palmaz stent, the Strecker 
stent and Be Stent were also noted to have this problem.
92, 93
  The risk of deformation 
lead to the withdrawal of these stents from routine use but the durability of the 
procedure has been shown to be equivalent in patients with and without deformed 
stents.
94
  Dedicated stent systems were in routine use at completion of the initial 
randomisation phase of the CAVATAS study in 1999.  Since then stent technology has 
advanced with the introduction of self expanding nitinol stents which have superior 
outcomes compared to the original stainless steel stents.
95, 96
  The increased use of 
intracerebral monitoring  by transcranial Doppler (TCD) has also confirmed that 
stenting appears to be safer than balloon angioplasty from a purely athero-embolic risk 
perspective.
97
   
 
Despite the technical adaptations carotid stenting and carotid endarterectomy continue 
to have 30 day complication rates of around 6% in randomised trials.  The CAVATAS 
study results were first released in abstract form with both the carotid endarterectomy 
and angioplasty / stenting arms showing equivalent complication rates of 6% at 30 days 
for disabling stroke or death.
98
  It must be remembered that the CAVATAS study was 
performed on the background of continued development of both techniques.  
Throughout the study surgeons were able to develop the carotid endarterectomy 
techniques making them more durable using patching material to prevent restenosis, 
99-
103
 and the radiologists developed protection devices and stents during the trial.  Yet 
despite these developments the 30 day complication rates remained similar to the 
original NASCET, and ECST trials performed 5 years prior to these developments.  
Final results of the CAVATAS study were published in 2001 showing no significant 
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difference between endovascular and surgical carotid procedures at 30 days.
40
  The 
maximum safety level of the procedures appeared to have been achieved and it did not 
appear at this point that complication rates could be lowered further.  This thesis 
contains work that was designed to seek ways to improve stenting outcomes further.
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iii) The role of antiplatelet agents, drug resistance and the rationale behind 
present anti-platelet therapies in carotid stenting. 
 
Medical therapy and specifically antiplatelet therapy prior to, during, and after carotid 
stenting has been shown to have a significant impact on the outcome from stenting 
procedures because the insertion of a metallic stent into an artery will always lead to 
activation of platelet dependant thrombotic pathways.
104
  Uncontrolled platelet 
activation will result in aggregation and thrombus formation with distal embolisation or 
stent occlusion in any patient undergoing stenting procedures. Platelet aggregation, the 
crucial step in thrombus formation, is mediated by the binding of activated platelets to 
fibrinogen through the platelet integrin glycoprotein IIb/IIIa.  Antiplatelet regimes used 
in stenting were developed to prevent this activation. 
 
Aspirin was administered to all patients to effectively inhibit collagen and arachidonic 
acid induced platelet aggregation and therefore thrombus formation within the stent.  As 
aspirin only affects a single pathway the IIb/IIIa platelet activation pathway is still 
capable of trigger thrombosis and stent related complications.  Thienopyridines such as 
Ticlopidine and Clopidogrel used synergistically with aspirin block ADP-induced 
activation of the IIb/IIIa receptor and consequently platelet aggregation.  These two 
therapies are key parts of the antiplatelet regime prior to stenting.  The combination 
prevents stable thrombus formation at the site of stent deployment and vessel 
endothelial injury and reduces embolic stroke risk.
105
  Patients undergoing coronary and 
carotid stenting are now routinely pre-treated with dual antiplatelet therapy consisting of 
aspirin and clopidogrel to reduce the impact of platelet activation on clinical outcomes.  
The benefit of this combination was first demonstrated clinically in cardiac stenting 
procedures but combination antiplatelet therapy has now also become the minimum 
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standard for endovascular carotid stenting procedures, and has been confirmed to be 
beneficial in randomised controlled trials.
9, 106
 
 
Dual antiplatelet therapy is administered prior to the stent insertion and is continued for 
4 weeks following insertion.  In theory this provides all patients with adequate 
suppression of platelet activation to prevent thrombotic-embolic complications from 
occurring in the immediate post operative period.  However, the large follow up series 
that have already been discussed show that cerebrovascular complications continue at a 
rate of 2 – 3% at 30 days follow up.  The terms, “aspirin resistance,” and “clopidogrel 
resistance,” have been used to describe sub groups of patients in whom varying levels of 
inhibition from these agents has been shown despite a standardised dosing regime.
107, 108
  
It has been assumed that patients with high levels of, “resistance,” to the drug are those 
more at risk of embolic complications but this has yet to be proven in carotid stenting.  
In a clinical setting demonstrating an increased risk using clinical outcomes as end 
points would require a trial of several thousand patients to provide any statistical power.  
Even if a higher risk group can be identified it is not clear what alternative agents could 
have a role in replacing aspirin and clopidogrel in these, "non responders.” 
  
Several alternative antiplatelet agents have been assessed for this purpose to date.  The 
antiplatelet agent Dextran 40 given as a continuous infusion has been assessed as part of 
the Leicester randomised trial between carotid endarterectomy and angioplasty.
62
  
Patients in this trial were treated with Dextran 40 if transcranial Doppler (TCD) 
monitoring detected more then 25 embolic signals occurring in any 10 minute period of 
monitoring for the first 6 hours after the procedures.
109-112
  Dextran works by reducing 
platelet adhesion, factor VIII activity, and increases clot lysis making it ideal for use in 
patients with active clot formation on stents. Unfortunately the Leicester trial was 
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terminated early due to unacceptable complication rates in the endovascular arm of the 
trial and Dextran has not been trialled since except as a rescue medication in patients 
with antiplatelet agent failure in carotid stenting.  One other case report has been 
published using dextran 40 as a successful rescue medication in a patient suffering a 
stroke whilst undergoing stenting; this patient had not received pre procedure 
clopidogrel and was in the non treatment arm for an alternative antiplatelet agent trial.
113
  
This patient had been taking S-nitrosoglutathione (GSNO) as an alternative agent to 
clopidogrel as part of a randomised trial.  S-nitrosoglutathione has been shown, like 
dextran 40, to have considerable success when assessed by transcranial Doppler (TCD) 
at reducing or eradicating embolic signals but has not been expanded to larger patient 
study.
114
 
 
Abciximab, a glycoprotein IIb/IIIa (Gp IIb/IIIa) receptor inhibitor, was first used in 
carotid stenting in 2000 by two groups in America and Israel.   The abciximab infusions 
were given peri-operatively and post operatively for 12 -16 hrs in place of routine 
clopidogrel in patients thought to have high risk arterial anatomy.
115, 116
  In both these 
studies no significant post operative neurological or bleeding complications occurred 
prompting further trials with Gp IIb/IIIa receptor blockers.  The later trials with these 
agents used them in addition to clopidogrel and aspirin in a,” belt and braces,” approach 
to ensure platelet deactivation because of the perceived risk of clopidogrel resistance.
117, 
118
  However, with larger studies it became apparent that these drugs lead to increased 
rates of serious intracranial bleeding complications, and their place in routine 
procedures has now been questioned.
119-121
  However, we must consider that these 
agents may be useful as a rescue therapy for the limited cases where rescue of a 
thrombosing stent is required, or embolic complications from a stent are occurring 
clinically on transcranial Doppler recordings.
122, 123
  They may also have a role in 
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patients where filter devices cannot be used safely.
124
  However, even in these 
circumstances it has been shown that they are not as efficient as embolic protection 
devices in reducing emboli numbers.
125
 
 
The limitations of other agents mean that the mainstay of antiplatelet therapy for 
prevention of stent thrombosis and thrombotic embolic events in carotid stenting 
procedures remains aspirin and clopidogrel.  Therefore, clopidogrel resistance could 
have a more significant impact on outcomes from carotid stenting procedures than has 
been seen in coronary stenting because most cardiologists employ a triple antiplatelet 
therapy approach.  To detect clinical differences in outcome from stenting procedures 
due to minor variations in clopidogrel platelet inhibition would have required hundreds 
of patient hours of follow up to demonstrate statistically significant outcomes.  The 
Effective Platelet Inhibition in Carotid Artery Stenting (EPICAS) study documented in 
this thesis was designed to utilise the previously described techniques of transcranial 
Doppler emboli detection as a surrogate endpoint for cerebrovascular damage in 
combination with platelet function assessments to ascertain what impact clopidogrel 
resistance may have clinically. 
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iv) Transcranial Doppler Ultrasound assessments during carotid stenting. 
 
Transcranial Doppler ultrasound (TCD) was first described in 1982 for monitoring 
intracerebral blood flow 
126
 and detecting cerebral vasospasm in patients undergoing 
catheter angiograms following subarachnoid haemorrhage.
127
  TCD use in carotid 
intervention was first documented in 1986 for monitoring middle cerebral artery (MCA) 
velocity during carotid endarterectomy, and later for the detection of cerebral micro 
embolic signals (MES) 
128
 in the Doppler wave form suggesting cerebral embolisation 
actively occurring from the operative field.
129
  Patients that suffered cerebrovascular 
complications with transcranial Doppler monitoring for embolic signals in place during 
and after carotid endarterectomy were shown to have higher numbers of embolic 
signals.
130
  It was suggested that embolic signal numbers represented a surrogate 
indicator of risk of ischemic complications from the procedure.
131
  Standard criteria for 
the detection of embolic signals were then agreed to allow this technique to be used 
reproducibly.
132
 
 
The first report of the use of transcranial Doppler ultrasound during endovascular 
carotid intervention was from Markus et al, London in 1994.
133
  They were able to 
demonstrate that micro embolic signals (MES) occurring during the procedure 
128
 could 
continue in the post operative period in the 10 patients they studied.  They postulated 
that TCD could therefore be used to monitor for the effects of medication on these 
events to reduce risk from the procedure.  Later reviews from the same group, and 
confirmed by other authors, suggested that endovascular procedures had higher rates of 
emboli in comparison with endarterectomy, but that clinically and in 
neuropsychological testing in a small series it was impossible to detect any difference in 
outcome from the two procedures.
134-137
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The timing of embolic events during catheter procedures has shown that a significant 
number of operative events associated with embolic showers occur intra operatively 
during wire and stent manipulation.
138
  These signals are most likely to be solid 
cholesterol emboli and it is difficult to see how these embolic events can be affected by 
antiplatelet therapies used in carotid artery stenting.  It is in the post operative period 
that the presence of embolic signals is likely to be due to platelet rich emboli and the 
benefits of antiplatelet agents in reducing the frequency of these signals can be studied.  
Transcranial Doppler has also been used to demonstrate differences between embolic 
loads dependant on the protection device type used during the procedure.  Filter devices 
have significantly higher operative embolic loads than balloon type occlusion 
devices.
139
  Filter devices also generate higher numbers of embolic particles than 
procedures without embolic protection,
140
 but these particles are of a smaller diameter 
and are postulated to be less likely to cause neuronal damage.
141
   The clinical 
significance of this finding is still as yet undetermined.  In the post operative period 
transcranial Doppler has confirmed that carotid stents are not a potent embolic source in 
medium (6 months) and long term follow up (12 months) after insertion.
142
   
 
 Transcranial Doppler detected embolic signal counts have been used successfully in 
carotid stenting trials to compare outcomes from new agents with routine therapy.
114
  
The techniques described allowed a new agent S-Nitrosoglutathione (GSNO) to be 
assessed against the standard regime of aspirin and heparin.  TCD endpoints 
demonstrated the superior efficacy of this agent by reducing post operative embolic 
signals.
114
  Micro embolic signal (MES) detection has also been used successfully in 
single and multicentre studies to monitor the effects of antiplatelet therapy in patients 
with symptomatic carotid artery disease by demonstrating significant reduction in the 
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number of MES in patients on differing antiplatelet regimes.
143-147
  The largest of these 
studies a multicentre randomised controlled study the Clopidogrel and Aspirin for 
Reduction of Emboli in Symptomatic carotid Stenosis (CARESS) trial 
143
 was published 
after the instigation of the EPICAS study in Sheffield but it provided reassurance that 
the methodology of the ongoing study was sound. 
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v) Scientific justification for the EPICAS study. 
 
The benefits of dual antiplatelet therapy over anticoagulation for prevention of 
thrombotic events has been confirmed in several cardiological and one carotid 
stenting trial to date.  The FANTASTIC study 
148
 and the SARS study 
149
 
demonstrate the benefits of dual antiplatelet regimes over anticoagulation with 
warfarin to prevent adverse events during coronary stenting and this was later 
confirmed by the CLASSICS study. 
150
  Randomised controlled trials later 
confirmed the benefits of the same dual antiplatelet regimes in carotid stenting and 
clopidogrel and aspirin are now considered a minimum standard of care for carotid 
and cardiac procedures.
9, 106
  However, despite a tested standardised regime with a 
sufficient pre treatment window with the anti platelet agents’ stroke and transient 
ischemic attacks due to embolic events continue to occur post procedurally in 
carotid stent patients.  
 
Some of these events are due to dislodged cholesterol emboli and carotid plaque 
material embolising after removal of the embolic protection device.  However, most 
of these events are likely to be athero embolic due to platelet aggregates.  This 
suggests that the either the doses of the agents used are insufficient, or an 
individual’s response to a standard dose varies dramatically from patient to patient 
allowing variable aggregation.  Maximum inhibition of the ADP mediated platelet 
aggregation pathway is not always possible in all patients even when they are pre 
loaded with clopidogrel.  Pre loading with 75mg of clopidogrel for one week or 
using a single loading dose of 300mg at least six hours prior to an endovascular 
procedure has been shown to be effective in the majority of patients, but not all.
151-
153
  Consequently, some authors advocate using higher doses of the drug in a single 
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loading dose if a full weeks preloading regime cannot be used.
154-157
  However, 
despite suggestions to try a higher single loading dose general agreement exists that 
using a preloading regime of one week’s therapy prior to the procedure will result in 
the maximum achievable platelet inhibition in each patient and these regimes are 
now recommended for all elective procedures.   
 
When developing the EPICAS study protocol it was hypothesised that an individual 
patient’s response to clopidogrel or aspirin would result in stenting failure and 
complications.  Multiple studies of in vitro platelet function testing of patients 
undergoing stenting procedures had suggested that between 10 – 20 % of all 
patients given dual therapy may respond poorly to clopidogrel.
108, 158-161
  This would 
mean that up to 20% of patients may be at increased risk of complication from the 
procedure.  However, assessing the effect that the varying degrees of platelet 
inhibition on a clinically relevant end point such as stroke, or transient ischemic 
attack or stent thrombosis remains difficult due to the low frequency that these 
events occur in stenting.  Carotid artery stenting provided an opportunity to study 
the impact of variable inhibition using transcranial Doppler (TCD) micro embolic 
signals as a surrogate end point for ischemia.  The accessibility of the carotid artery 
meant it could also serve as a model for thrombotic events occurring in all types of 
stenting procedures.   
 
It is well documented that micro embolic signals are often detected in the first 24 hours 
after angioplasty, stenting and carotid endarterectomy.
133, 137, 162, 163
  This is the period 
when platelet micro aggregates are most likely to have formed on the stent surface.  
They are also are more frequent immediately after the procedure particularly within the 
first few hours.  Combining this information with evidence that suggests the number of 
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embolic signals detected can act as a positive predictor of future stroke risk 
131, 164, 165
, 
and data suggesting that clinical complication rates from angioplasty and stenting may 
be highest in the first 24 hours, we predict that eliminating embolic signals should act as 
a surrogate marker for reducing complication risk.  Previous studies have already 
demonstrated that this approach was beneficial to examine the effects of new 
medications used during carotid procedures.
114, 143-147
  The EPICAS study aimed to see 
if these techniques were useful in determining the effects of, “clopidogrel resistance,” 
on embolic counts. 
 
All patients continue on antiplatelet therapy for a period of four weeks after the stenting 
procedure until the stent is presumed to have endothelialised.  It has been suggested that 
endothelialisation may take up to 96 days 
166
, and therefore a period of clopidogrel 
therapy given for only 4 weeks may be insufficient.  Previously published data has 
already shown that at six months the stent no longer acts as a source of micro emboli 
142
, but at present no information is available to suggest an appropriate length of time 
for the clopidogrel therapy to continue.  Performing TCD after discontinuation of dual 
antiplatelet therapy may show recurrence of embolic events suggesting longer therapy 
windows should be investigated and therefore was investigated as part of the EPICAS 
protocol. 
 
Combining the techniques of platelet function testing and transcranial Doppler 
ultrasound to develop a model that allows pre procedure platelet analysis to predict 
possible post procedure complication risk was the primary aim of this research.  The 
study protocol was designed by Dr M.Randall and with assistance from Prof G. 
Venables and Prof P. Gaines and Dr R Storey.  This thesis contains the outcomes of this 
research.  The preliminary analysis of the Sheffield cohort data highlights patient 
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selection and correct indication for stenting in the case of the pre operative stents for 
cardiac bypass as primary effectors of outcome.  The EPICAS study then focused on the 
use of clopidogrel highlighted in this preliminary work as an opportunity to improve 
outcomes.
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2 Lessons from the Sheffield endovascular cohort – 
Multivariate analysis of a prospectively maintained database 
of 30 day and Long term outcomes. 
 
Introduction 
 
Cerebrovascular disease costs the economies of the European Union €34 billion per 
annum, with 62% of these costs directly related to health care expenditure.
167
  Carotid 
artery disease is implicated in approximately 25 % of ischemic stroke cases.
168
   
NASCET and ECST trialists demonstrated the benefits of surgery over best available 
medical therapy at the time to prevent recurrent carotid territory ischaemic events.
26, 169
  
Carotid stenting, an alternative to carotid endarterectomy, is undergoing evaluation in 4 
multinational randomised controlled trials.
170-173
  Analysis of the 30 day outcomes of 
EVA-3S, and SPACE 
170, 173, 174
 has been published and follow up analysis of both these 
trials is in press.  The 30 day outcomes from ICSS have been presented at the European 
Stroke conference.
175, 176
  When combined with the meta-analysis of carotid angioplasty 
trials we have reasonably robust data on  possible risks from the stenting procedure.
177
  
The SAPPHIRE and CARESS investigators suggest non inferiority of the stenting 
procedure in short and long-term follow up when investigating mixed cohorts of 
symptomatic and asymptomatic patients.
178-180
   
 
The clinical trial data suggests that carotid stenting is as durable as carotid 
endarterectomy in the long term although may have higher risks peri procedurally at 30 
days.  In addition to trial data, cohort studies allow outcomes to be analysed from 
representative clinical practice.  All previous cohort studies contained both symptomatic 
 37 
 
 
and asymptomatic patients, the majority being asymptomatic patients.
181-185
  To address 
this we devised our cohort analysis on prospectively collected, audit department 
approved, stenting data of recently symptomatic patients only.  We attempted to assess 
if procedural factors, patient factors, or restenosis had any impact on long term 
outcomes from stenting procedures.  We focused on those highlighted by previous work 
from the ECST dataset 
186
 and mixed cohorts of symptomatic and asymptomatic 
patients undergoing stenting.
181, 183, 187-189
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Methodology 
 
Patients with recent carotid territory, cerebral or retinal ischaemia, and carotid artery 
stenosis greater than 70% (NASCET criteria) on angiogram, have been considered for 
endovascular carotid intervention in our centre since 1993.  Treatment 
recommendations are made by a neurology / vascular surgery / vascular radiology 
multidisciplinary team.  All patients are screened with carotid duplex and brain CT.  
Patients with carotid artery stenosis of greater than 60% on duplex undergo arch 
aortography,
190
 or magnetic resonance angiography (MRA) to confirm the stenosis and 
anatomy of the carotid vessels origins.  Patients suitable for either endarterectomy or 
stenting are invited to participate in randomised intervention trials.  Patients unsuitable 
or unwilling to undergo carotid endarterectomy are offered carotid stenting outside of 
these trials.  
 
Prospective data collection is performed by a neurologist for each patient, including a 
pre operative assessment by a neurologist (MSR, FMcK, SK or GSV).  The database is 
maintained in accordance with the National Health Service and Sheffield Teaching 
Hospital Clinical Effectiveness Unit Service Evaluation Audit policies (database 
registration 2212).  Stenting procedures are performed by interventional vascular 
radiologists (TJC, PAG).  The techniques have been described in previous publications 
from our centre.
4, 9
  From 1996 to 2006 our stenting technique has developed to include 
the use of cerebral protection devices whenever possible, and mandatory use of dual 
antiplatelet therapy.
9
  Dual therapy with clopidogrel and aspirin continues for 28 days 
after stenting, before reverting to aspirin or since 2004 aspirin and dipyridamole.  A 
small number of patients’ stented before 2002 received only a 14 day course of dual 
therapy. 
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Post stenting neurological assessment was performed by a neurologist at 24 hours or 
discharge if earlier.  Neurological complications were classified as ; Amaurosis fugax - 
monocular visual loss less than 24 hours, transient ischaemic attack - new neurological 
deficit less than 24 hours, Minor stroke - new neurological deficits more than 24 hours 
but less than 7 days, and Major stroke - new neurological deficit persisting more than 7 
days. The Oxford modified handicap score was used to categorise non-disabling (score 
0-2) from disabling stroke (score ≥3).191   
 
30 day and yearly follow up was performed in specialist clinics by a neurologist, or 
stroke specialist nurse / radiologist with neurological support.  All patients underwent 
duplex ultrasound at 30 days, yearly follow up visits or at time of recurrent event when 
possible to assess for restenosis.  Validated criteria for restenosis have been used.
192
  
Patients missing or, “lost to follow up”, were traced and contacted by telephone.  Deaths 
were confirmed from medical records, or death certificates obtained from the General 
Register Office (www.gro.gov.uk).  Data collection was not routinely performed in all 
patients after 5 years follow up and therefore was censored at this point for the purposes 
of analysis. 
 
Statistical Analysis 
Statistical analysis was performed using SPSS 15.0.1 software package.  Event rates per 
thousand patient years of follow up were calculated. Univariable analysis was 
performed using Kaplan Meier and Cox survival analysis.  A Cox’s proportional 
hazards model for multivariable analysis using a 0.10 cut off after co-linear variables 
had been screened and the least significant variable discarded was then used.  The 
analysis was repeated with year of procedure forced into the model to see if the global 
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effect of improved technique and experience impacted on the outcomes.  Restenosis was 
entered as a time dependant variable in the modelling after assessment of residuals, age 
and year of procedure were similarly assessed for effect of time and they were not 
shown to have a significant time dependant element after assessment.  Analysis was 
performed for end points of ipsilateral stroke, ipsilateral stroke or vascular death, and all 
stroke and death.   
 
Possible predictors of 30 day outcomes were examined using Chi square for discrete 
data and student’s t test for continuous data before undertaking multivariable analysis 
using multiple logistic regression.  This analysis has been tabulated.  
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Results 
 
Between March 1996 and August 2008 562 carotid stenting procedures were performed 
on symptomatic carotid vessels, with follow up until Sept 2008.  The mean follow up 
was 3.5 yrs, the median 4 yrs, and the range 30 days - 5 years.  The presenting 
complaint was a retinal event in 144 (25.6%) cases.  Baseline characteristics and rates of 
medication use at baseline of the patients treated are shown in Table 1.  Hypertension 
was defined by internationally recognised criteria.
193
  Clopidogrel was used in addition 
to aspirin in 413 patients (73.6%). 
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Table 1 Baseline Characteristics 
 
 n = 563 
Mean Age [Range] 68.5 [42 – 89] 
Patients aged over 80 years old (%) 65 (11.5%) 
Male (%) 381 (67.6%) 
Carotid treated Left : Right 282 : 281 
Mean time from event (months) [Range] 3.2 [0 – 13]  
Treated within 1 month of symptoms 141 (25.1%) 
Presenting event      Retinal : Cerebral 144 : 419 
Hypertensive 
*
 376 (67%) 
Ischaemic heart disease 199 (35.5%) 
Hypercholesterolemia † 442 (78.8%) 
Diabetes 99 (17.6%) 
 Type II diabetes 87 (15.4%) 
Smoking history  427 (75.7%) 
 Current smoker 128 (22.8%) 
Medication use at time of stent  
 Clopidogrel 413 (73.6%) 
 Statin 381 (67.9%) 
 Beta Blocker 77 (13.7%) 
 ACE inhibitor / AII blocker 145 (25.7%) 
Stent design Open : Closed 92 : 470 
 Carotid Wallstent 439 (77.9%) 
 Precise 38 (6.7%) 
Protection device used Any device 362 (64.3%) 
 Filter EZ devices 289 (51.2%) 
Total amount of follow up 1945 patient years 
 
* British Hypertension society guidelines (grade 1) 
193
 or on medication 
†  
Total cholesterol > 5mmol/l 
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At four years of follow up a total of 34 ipsilateral strokes had occurred.  Of these events 
17 patients had suffered a minor ipsilateral stroke, 12 patients’ major ipsilateral strokes 
and 5 stroke deaths had occurred.  Applying Kaplan Meier survival analysis to the entire 
data set allows for censored and missing data to be taken into account and predicts 
ipsilateral stroke rates % (±SE) of 4.8% (±0.9), 7.0% (±1.1), 8.0% (±1.2), 8.5% (±1.2), 
9.5% (±1.3), and 10.7% (±1.5) at 30 days, one, two, three, and four. and five years 
respectively.  Stroke rates were then re calculated for the, “optimised,” therapy of 
clopidogrel, statin and embolic protection as well as for each of the elements 
individually.  The rates for patients considered high surgical risk by the SAPPHIRE trial 
criteria were also calculated and no difference was seen between groups considered to 
be high and low risk (p=0.592).  The results are tabulated in Table 2. 
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Table 2 Kaplan Meier calculated Ipsilateral stroke free survival rates.  
(Comparison with Mantel Cox Log Rank test.) 
 
 
Number of 
patients 
30 days 1 year 4 years Log rank 
 
Stroke free 
survival  % 
(SE) 
Stroke free 
survival % (SE) 
Stroke free 
survival % (SE) 
p 
Overall 563 95.2 (0.9) 93.0 (1.1) 90.5 (1.3)  
         
Optimal 296 97.3 (0.9) 95.9 (1.2) 95.2 (1.2) 
< 0.001 
Sub Optimal 267 92.9 (1.4) 89.9 (1.9) 85.8 (2.2) 
         
Protected 362 96.7 (0.9) 95.3 (1.1) 94.1 (1.3) 
< 0.001 
Unprotected 201 92.5 (1.9) 89.0 (2.2) 85.0 (2.6) 
         
Statin 381 97.4 (0.8) 95.2 (1.1) 93.8 (1.3) 
< 0.001 
No Statin 180 90.6 (2.2) 88.3 (2.4) 84.1 (2.8) 
         
Clopidogrel 413 97.3 (0.8) 95.6 (1.0) 94.1 (1.3) 
< 0.001 
No clopidogrel 148 89.2 (2.6) 85.8 (2.9) 81.3 (3.2) 
         
High Surgical 
Risk 
240 95.4 (1.4) 94.1 (1.5) 91.3 (2.0) 
0.592 
Low Surgical Risk 323 95.7 (1.1) 92.2 (1.5) 89.9 (1.7) 
         
Trial patients 227 92.1 (1.8) 91.1 (1.1) 90.0 (2.0) 
0.741 
Non trial patients 336 94.6 (1.2) 94.3 (1.3) 90.8 (1.8) 
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To compare with previous groups univariable survival analysis for end points of stroke, 
or stroke and vascular death, was performed using Kaplan Meier and Cox proportional 
hazards analysis (Table 3).  Crossing hazards on the Kaplan Meier plots were tested for 
chance by testing for an interaction with time, no interaction was seen.  Statistically 
significant variables on the outcome of recurrent ipsilateral stroke included; mode of 
presentation (p= <0.001), presence of hypercholesterolemia (p=0.003), the use of 
clopidogrel (p=0.001), statins (p= <0.001), and protection devices (p= <0.001), the 
presence of a recurrent stenosis of >50 % (p=0.008) analysed as time dependant, and the 
calendar year of treatment (p=0.004).  Figure 1 shows the Kaplan Meier curves for 
these outcomes.  Analysis was repeated for recurrent ipsilateral stroke or vascular death, 
and ipsilateral stroke or any death as outcome measures (Table 3). 
  
 
 
Table 3 Univariable assessment causing recurrent ipsilateral stroke, stroke and vascular death and stroke or any death with time post 
stent insertion. Kaplan Meier analysis for nominal variables, COX analysis for continuous and time dependant variables. 
Variable  N 
Ipsilateral Stroke Ipsilateral Stroke or Vasc. Death Ipsilateral Stroke or Any Death 
Event rate / 1000 pt 
years follow up 
p 
Event rate / 1000 pt 
years follow up 
p 
Event rate / 1000 pt 
years follow up 
p 
Sex M : F 380 : 182 0.07 : 0.17 0.709 0.11 : 0.22 0.762 0.17 : 0.32 0.602 
Side Treated L : R 282 : 281 0.10 : 0.10 0.887 0.14 : 0.15 0.732 0.24 : 0.20 0.354 
Clinical trial Y : N 227 : 363 0.13 : 0.08 0.741 0.19 : 0.12 0.648 0.26 : 0.19 0.680 
SAPPHIRE risk Low : High 324 : 239 0.09 : 0.11 0.592 0.11 : 0.20 0.225 0.15 : 0.35 0.004 
Age <80 : >80 497 : 65 0.06 : 0.36 0.406 0.08 : 0.90 0.517 0.11 : 1.91 0.002 
Presentation Retinal : Cerebral  144 : 419 0.05 : 0.08 0.001 0.10 : 0.12 < 0.001 0.22 : 0.18 < 0.001 
Stent design Open : Closed 91 : 470 0.27 : 0.06 0.541 0.46 : 0.09 0.958 0.53 : 0.14 0.261 
Hypertension Y : N 376 : 185 0.07 : 0.17 0.497 0.11 : 0.23 0.793 0.17 : 0.34 0.948 
IHD Y : N 199 :362 0.15 : 0.08 0.718 0.24 : 0.10 0.284 0.42 : 0.14 0.008 
Hypercholesterolemia Y : N : DK 442 : 86 : 33 0.05 : 0.68 : 1.73 < 0.001 0.06 : 0.89 : 2.38 < 0 .001 0.11 : 1.44 : 3.03 < 0.001 
Smoking history Y : N 427 : 134 0.06 : 0.24 0.484 0.09 : 0.32 0.667 0.15 : 0.45 0.948 
Diabetes Y : N 99 : 462 0.46 : 0.05 0.056 0.73 : 0.08 0.002 1.03 : 0.12 0.002 
Clopidogrel Y : N 413 : 148 0.04 : 0.33 < 0.001 0.07 : 0.41 < 0.001 0.14 : 0.55 0.002 
Statin Y : N 381 : 180 0.04 : 0.25 < 0.001 0.07 : 0.35 < 0.001 0.12 : 0.51 <0.001 
Beta Blocker Y : N 77 : 484 0.50 : 0.06 0.404 0.55 : 0.08 0.925 0.82 : 0.13 0.948 
ACE / AII inhibitors Y : N 145 : 416 0.13 : 0.07 0.098 0.21 : 0.10 0.148 0.32 : 0.16 0.089 
Protection Device Y : N 362 : 208 0.05 : 0.20 < 0.001 0.08 : 0.28 < 0.001 0.15 : 0.37 0.007 
         
  Mean HR (95% CI)  p HR (95% CI) p HR (95% CI) p 
Age Years 68.53 0.994 (0.965 – 1.024) 0.708 1.020 (0.994 – 1.046) 0.129 1.037 (1.016 – 1.059) 0.001 
Delay to treatment Months 3.24 1.101 (0.980 – 1.237) 0.106 1.079 (0.976 – 1.194) 0.137 1.024 (0.940 – 1.114) 0.589 
Restenosis > 50 %   0.412 (0.215 – 0.789) 0.008 0.511 (0.270 – 0.965) 0.038 1.626 (0.886 – 2.985) 0.117 
Year of treatment   0.843 (0.770 – 0.924)  < 0.001 0.860 (0.796 – 0.929) < 0.001 0.928 (0.873 – 0.987) 0.017 
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Figure 1 Kaplan Meier Curves of variables assessed in Univariable analysis 
for the outcome of recurrent ipsilateral stroke.  Comparison between variables 
with Log Rank statistic 
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Multivariable analysis was then applied to all the variables included in table 3 after 
screening for confounders a p ≤ 0.10 was used as the cut off for backward selection, the 
remaining significant variables that were reassessed are shown in (Table 4).  Retinal 
presentations (HR = 0.228, CI 0.082 – 0.632, p = 0.004) had lower risk of recurrent 
stroke, and the presence of persistent or recurrent stenosis of greater than 50% (HR = 
2.187, CI 1.173 – 4.078, p = 0.014) was a risk factors for recurrent ipsilateral stroke.  
Clopidogrel use during the procedure has an impact on reducing the risk for recurrent 
ipsilateral stroke (HR = 0.318 CI 0.185 – 0.545, p = <0.001).  A further analysis was 
undertaken with calendar year of the procedure forced into the model but made no 
difference to the outcome. 
  
Table 4 Multivariable assessment using Cox proportional hazards assessment of independent contribution towards further ipsilateral 
stroke, stroke or vascular death and stroke and any death post stent insertion. 
Variable 
Ipsilateral Stroke Ipsilateral Stroke or Vascular death Ipsilateral Stroke or death 
HR 95% CI P HR 95% CI p HR 95% CI p 
Age 
   1.019 (0.994 - 1.045) 0.139 1.031 (1.010 - 1.053) 0.004 
Retinal Presentation 
0.228 (0.082 - 0.632) 0.004 0.278 (0.128 - 0.605) 0.001 0.460 (0.271 - 0.780) 0.004 
Diabetes 
1.693 (0.919 - 3.118) 0.091 2.091 (1.267 - 3.451) 0.004 1.921 (1.269 – 2.908) 0.002 
Clopidogrel 
0.318 (0.185 – 0.545) < 0.001       
Statin 
      0.424 (0.296 - 0.608) < 0.001 
Beta Blocker 
1.655 (0.805 – 3.403) 0.170       
Restenosis > 50% 
2.187 (1.173 – 4.078) 0.014 1.148 (0.603 – 2.186) 0.674 0.370 (0.177 – 0.775) 0.008 
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Figure 2 Multivariable COX analysis of variables impact on long term 
recurrence of ipsilateral stroke. 
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Inspecting the Kaplan Meier curves suggests that 30 day outcomes have significant 
impact on long-term outcomes in common with previous publications.
174, 187, 188
  
Univariable and multivariable analysis of 30 day outcomes was performed to identify 
these variables. The results of the univariable analysis can be seen in table 5 
Multivariable logistic regression analysis showed cerebral presentation to have a hazard 
6 times greater than retinal presentation (HR 6.668 CI 1.498 – 26.689, p = 0.013).  
Clopidogrel use (HR 0.291 CI 0.100 – 0.841, p = 0.023) was shown to be an 
independent variable lowering ipsilateral stroke recurrence at 30 days with Diabetes 
increasing the risk of an adverse event (HR 2.361 CI 1.052 – 5.302, p = 0.037) (Table 
6). 
  
 
 
Table 5 Univariable assessment of variables influence on 30 day outcomes from stroke and stroke and vascular death. (Chi square, 
Fishers and Student T test) 
 
Variable  Number of 
patients 
Ipsilateral Stroke Ipsilateral Stroke or Vasc Death Ipsilateral Stroke or any Death 
  % stroke rate   p % stroke rate P % stroke rate p 
Sex M : F 380 : 182 6.8 : 5.5 0.587 7.4 : 6.0 0.723 7.6 : 6.6 0.731 
Side treated L : R 282 : 281 7.1 : 5.7 0.606 7.8 : 6.1 0.507 8.5 : 6.1 0.331 
Clinical trial Y : N 227 : 363 7.9 : 5.4 0.226 8.4 : 6.0 0.311 8.4 : 6.6 0.415 
SAPPHIRE risk Low : High 324 : 239 7.1 : 5.5 0.489 7.4 : 6.3 0.737 8.0 : 6.3 0.513 
Age <80 : >80 497 : 65 6.5 : 6.2 0.927 6.9 : 7.7 0.795 7.5 : 6.2 0.704 
Presentation Retinal : Cerebral 144 : 419 1.4 : 8.1 0.003 1.4 : 8.8 0.001 2.8 : 8.8 0.015 
Stent design Open : Closed 91 : 470 6.7 : 6.4 0.891 7.0 : 6.7 0.904 6.7 : 7.4 0.795 
Hypertension Y : N 376 : 185 6.7 : 5.9 0.855 7.5 : 5.9 0.598 7.7 : 6.5 0.731 
IHD Y : N 199 :362 5.1 : 7.2 0.372 6.1 : 7.5 0.605 6.6 : 7.7 0.735 
Hypercholesterolemia Y : N : DK 442 : 86 : 33 4.5 : 11.6 : 18.2 0.001 5.0 : 11.6 : 21.2 < 0.001 5.2 : 12.8 : 21.2 < 0.001 
Smoking Hx Y : N 427 : 134 5.4 : 9.7 0.104 5.6 : 11.2 0.038 6.3 : 10.4 0.128 
Diabetes Y : N 99 : 462 11.1 : 5.4 0.043 11.1 : 6.1 0.083 10.1 : 6.7 0.285 
Clopidogrel Y : N 413 : 148 3.6 : 14.2 < 0.001 4.1 : 14.9 < 0.001 4.4 : 15.5 < 0.001 
Statin Y : N 381 : 180 3.9 : 11.7 0.001 4.5 : 12.2 0.001 4.7 : 12.8 0.001 
Beta Blocker Y : N 77 : 484 6.6 : 6.4 0.954 7.0 : 6.6 0.887 6.6 : 7.4 0.789 
ACE / AII block Y : N 145 : 416 4.1 : 7.2 0.239 4.1 : 8.0 0.133 4.8 : 8.2 0.200 
Protection device Y : N 362 : 208 4.2 : 10.4 0.006 4.7 : 10.9 0.009 5.0 : 11.4 0.006 
Age Years   0.243  0.200  0.259 
Delay to Tx Months   0.301  0.245  0.228 
Year of treatment    0.010  0.017  0.001 
  
 
Table 6 Multivariable analysis of variables effect on 30 day outcome from stroke, stroke and vascular death and stroke and death.  
Multiple logistic regression analysis. 
Variable  Number of 
patients 
Ipsilateral Stroke Ipsilateral Stroke or Vascular 
Death 
Ipsilateral Stroke or any Death 
  % stroke rate   p % stroke rate P % stroke rate P 
Sex M : F 380 : 182 6.8 : 5.5 0.587 7.4 : 6.0 0.723 7.6 : 6.6 0.731 
Side treated L : R 282 : 281 7.1 : 5.7 0.606 7.8 : 6.1 0.507 8.5 : 6.1 0.331 
Clinical trial Y : N 227 : 363 7.9 : 5.4 0.226 8.4 : 6.0 0.311 8.4 : 6.6 0.415 
SAPPHIRE risk Low : High 324 : 239 7.1 : 5.5 0.489 7.4 : 6.3 0.737 8.0 : 6.3 0.513 
Age <80 : >80 497 : 65 6.5 : 6.2 0.927 6.9 : 7.7 0.795 7.5 : 6.2 0.704 
Presentation Retinal : Cerebral 144 : 419 1.4 : 8.1 0.003 1.4 : 8.8 0.001 2.8 : 8.8 0.015 
Stent design Open : Closed 91 : 470 6.7 : 6.4 0.891 7.0 : 6.7 0.904 6.7 : 7.4 0.795 
Hypertension Y : N 376 : 185 6.7 : 5.9 0.855 7.5 : 5.9 0.598 7.7 : 6.5 0.731 
IHD Y : N 199 :362 5.1 : 7.2 0.372 6.1 : 7.5 0.605 6.6 : 7.7 0.735 
Hypercholesterolemia Y : N : DK 442 : 86 : 33 4.5 : 11.6 : 18.2 0.001 5.0 : 11.6 : 21.2 < 0.001 5.2 : 12.8 : 21.2 < 0.001 
Smoking Hx Y : N 427 : 134 5.4 : 9.7 0.104 5.6 : 11.2 0.038 6.3 : 10.4 0.128 
Diabetes Y : N 99 : 462 11.1 : 5.4 0.043 11.1 : 6.1 0.083 10.1 : 6.7 0.285 
Clopidogrel Y : N 413 : 148 3.6 : 14.2 < 0.001 4.1 : 14.9 < 0.001 4.4 : 15.5 < 0.001 
Statin Y : N 381 : 180 3.9 : 11.7 0.001 4.5 : 12.2 0.001 4.7 : 12.8 0.001 
Beta Blocker Y : N 77 : 484 6.6 : 6.4 0.954 7.0 : 6.6 0.887 6.6 : 7.4 0.789 
ACE / AII block Y : N 145 : 416 4.1 : 7.2 0.239 4.1 : 8.0 0.133 4.8 : 8.2 0.200 
Protection device Y : N 362 : 208 4.2 : 10.4 0.006 4.7 : 10.9 0.009 5.0 : 11.4 0.006 
Age Years   0.243  0.200  0.259 
Delay to Tx Months   0.301  0.245  0.228 
Year of treatment    0.010  0.017  0.001 
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iv) Discussion of the Sheffield analysis. 
 
Publications in press from the randomised controlled trials suggest that in the long term 
carotid stenting appears to be as durable as carotid endarterectomy in preventing future 
vascular events despite a higher 30 day risk.
175, 176
  They highlight that 30 day peri-
operative event rates contribute to the majority of the excess recurrence in stenting.
175
  
Our Kaplan Meier stroke free survival rates for the complete dataset 4.8% (±0.9), 7.0% 
(±1.1), 8.0% (±1.2), 8.5% (±1.2), 9.5% (±1.3), and 11.3% (±1.5) at 30 days, one, two, 
three, four. and five years respectively compare favourably with the data from the 
RCT’S of carotid stenting and surgery, suggesting the durability of the procedure can be 
maintained when patients not conforming to  RCT entrance criteria are included in 
outcome analysis.
26, 40, 175, 176, 185
 
 
Outside of a randomised controlled trial patient selection is less rigorous and exclusive, 
and comparative cohort studies such as this one are useful to support data from RCT’s 
in real life situations by including patients not eligible for trials.  To date one other 
cohort study stenting purely symptomatic patients, with a mean follow up 25 months, 
has been published.
183
  The focus of this study was on the impact of stents to prevent 
restenosis in place of angioplasty and not to identify the alternative risk factors 
undertaken in this analysis.  Stent use did significantly reduced rates of restenosis of 
>70% but did not affect long-term outcome measures.
183
  However, the role of 
restenosis on recurrent outcomes in stented patients has yet to be proven, and the 
SPACE and SAPPHIRE groups disagree over its rate in comparison to 
endarterectomy.
180
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The purpose of our analysis was to look at multiple factors affecting long term stroke 
free survival, using elements suggested previously to affect outcome to see if they are 
true independent predictors of recurrent events.
186
  Our long-term experience of stenting 
symptomatic carotid vessels presented here provides evidence for the combined benefits 
of the individual elements now making up the perceived minimum standard of care for a 
stenting procedure, but individual effects of pharmacological agents on recurrent events 
were of particular interest.
9, 194
  Numerous modifications to the carotid stenting 
procedure have occurred in a short space of time making determination of the individual 
changes difficult to detect any other way.  It would now be impossible to reverse 
developments and assess each change individually.  The heart protection study in 2002 
195
 showed that all stroke or TIA patients, and therefore any patient requiring carotid 
stenting for a symptomatic carotid stenosis, should be offered statin therapy.  Therefore, 
the effects of statin therapy on the long term outcomes from stenting can now only be 
assessed with this form of multivariable analysis not a randomised controlled trial.  
Dual antiplatelet therapy with aspirin and clopidogrel is another example that has 
become standard therapy at our institution from 2002 after clear benefit of the regime on 
30 day outcomes was shown in a randomised trial comparing with aspirin and heparin.
9
   
 
Multivariable analysis in this case showed only clopidogrel had clear independent 
benefit on the outcomes of ipsilateral stroke and vascular death in the long term follow 
up, despite statin and clopidogrel therapy appearing to be beneficial in univariate 
analysis.  We have not, as we had hoped, been able to separate out individual effects of 
the other pharmacological therapies and this may never be possible as most were 
introduced around the same time.  The impact of clopidogrel on long term outcomes is 
likely to be due to its dramatic effects at 30 days.  This raises questions about the 
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possible benefits of prolonging post stenting clopidogrel therapy to see if this benefit 
can be extended longer.
152
   
 
In common with the endarterectomy trials we have confirmed that retinal events have a 
significantly lower risk of future recurrence than cortical events.
186, 196
  A significant 
proportion of this is due to the effect on 30 day outcomes shown here and by other 
authors.
187
  Our analysis has also highlighted that recurrent stenosis of greater than 50% 
is likely to contribute as an independent risk factor for an event.  This effect appears to 
date from the time of the procedure in some cases and therefore must represent residual 
stenosis from the procedure as restenosis should not have developed in this time.  
Although this is likely to be the case we cannot call this residual stenosis as we have no 
data to show that the stenosis dates exactly from the time of the procedure because post 
stenting angiograms were not reviewed as part of the analysis.  The first imaging data 
we have available on the patients is at 30 day follow up and it is conceivable although 
unlikely that stenosis developed in this short time.  In the case of the early stents, which 
were not carotid specific and have been shown to have a liability to collapse this could 
be the case. 
92, 93
 
 
If this can be confirmed in analysis of another co-hort it suggests very strongly to all 
carotid stenting practitioners that they should not leave a high grade residual stenosis.  It 
is also noted that statistical analysis of our patients is suggesting that restenosis may be 
protective against the combined end point of recurrent stroke and all death.  However, 
this is most likely a statistical anomaly and probably reflects the fact that death from 
other cause is affecting a greater proportion of these patients at 4 year follow up diluting 
the impact of the restenosis on the outcome of stroke. 
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This analysis has investigated variables only previously subjected to univariable 
analysis in other studies.  The impact of pre existing ischaemic heart disease on any of 
the outcome measures suggested by previous studies 
182
 has not been demonstrated.  
Increasing age has also been previously shown to be a risk factor for 30 day adverse 
events, 
174, 197
 but this was not confirmed in our series analysed as either a continuous or 
nominal (age >80) variable for  short and long-term outcomes in common with another 
recently published series.
189
  What is clear from this analysis is that detection of effects 
from individual changes in procedural technique is not likely to be possible with data 
available to us.  However, when the therapies are analysed as a combination the impact 
on outcome is dramatic in the long term.  Prior to all patients receiving dual antiplatelet 
therapy, statin therapy and the routine use of a protection device 7.2 % of patients 
experienced recurrent ipsilateral stroke at 30 days, when these therapies became 
standard the rates reduced to 2.6%.  The benefits are then continued into long term 
follow up and impact on the Kaplan-Meier calculated outcomes at one, two and three 
years.  It is therefore important that the effect of these procedural developments is 
considered when analysis of the randomised trials is performed and may explain some 
of the differences demonstrated between endarterectomy and stenting at 30 days in 
SPACE, EVA3S and the International Carotid Stenting Study (ICSS) recently presented 
at the European Stroke Conference. 
 
Previous cohort studies had limitations that we attempted to minimise in our analysis by 
using larger numbers, purely symptomatic patients, and longer follow up.  Our study 
analyses symptomatic patients and in a centre performing endovascular carotid 
intervention from 1993 and carotid stenting from 1995.  This minimises the, “learning 
curve effect,”  on the outcomes in most of the patients described here.198, 199  The year 
the procedure was undertaken was forced into the multivariable analysis to account for 
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learning and changing technique and was not shown to be independently significant.  
Our study is not without limitations.  Prospectively collected data in sequential patients 
overcomes recall bias, but missed patients introduce selection bias.  Our cohort also 
includes symptomatic patients felt to be unsuitable for carotid endarterectomy due to 
high surgical risk, anatomical or morphological reasons, but this did not seem to affect 
outcomes when analysed by inclusion in a trial or by SAPPHIRE risk.
174-176
  Our 
patients were reviewed by a neurologist, not the interventionalists, after the procedure to 
reduce under reporting of outcomes and may have lead to higher detection rate of minor 
neurological events.   
 
This study is presently the most extensive multivariable cohort analysis of purely 
symptomatic patients under follow up and has attempted to assess the impact of 
restenosis and time to restenosis.   Patients treated as part of this cohort study have been 
treated at varying time points from the time of the event.  Patients treated more recently 
have been treated within 4 weeks, but we do accept that some of the earlier patients 
treated were several months after the time of their event and in a more modern 
classification would be considered to be asymptomatic which may have an impact on 
the outcome rates.  However, the study remains the largest of its kind currently 
published and highlights some interesting points to be investigated in the larger cohorts 
in the randomised trials. 
 
The effects of individual procedural changes are too small to detect but it suggests 
optimal patient selection and combination therapy has the most significant impact on 
long-term outcome and 30 day complications.  The issue of residual or restenosis of 
greater than 50% has been highlighted as a possible risk factor for recurrent stroke 
 60 
 
events and needs more investigation, but in the first instance practitioners should ensure 
that they leave as little residual stenosis as possible. 
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3 Routine stenting of asymptomatic carotid stenosis pre 
CABG - Safety and suitability of this procedure from analysis 
of the Sheffield registry. 
 
i) Introduction 
 
Perioperative stroke and ischaemic encephalopathy are two well recognised 
complications of coronary artery bypass grafting and heart valve replacement surgery.  
The risk of stroke in the perioperative period has remained around 2% for the past three 
decades.  The presence of carotid disease in patients undergoing coronary artery bypass 
surgery has been shown to increase this risk of perioperative stroke from the cardiac 
procedure threefold.
200
  This finding provided a logical reason for the initial trials of 
combined or staged carotid endarterectomy in these patients in an attempt to reduce 
peri-operative mortality.  The contribution of the carotid disease in direct causation of 
perioperative stroke has been difficult to prove.  It has been hypothesised that 
significant carotid disease exacerbated the effects of periods of intra operative 
hypotension during cardiac bypass, resulting in relative cerebral hypoperfusion causing 
intra-operative stroke.  However, it is also conceivable that the presence of high grade 
carotid disease is purely an indicator of higher cardiovascular morbidity in these 
patients.  Intra operative monitoring using Transcranial Doppler ultrasound has 
demonstrated that athero-embolism occurring as a result of aortic cross clamping is 
common and also contributes to the intra operative stroke risk.
201
  It is conceivable, 
although unproven that stenotic carotids may have protected a sub group of patients 
from embolic neurological complications. What is now clear is that the aetiology of 
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stroke during cardiac surgery is multi-factorial and carotid stenosis is likely to play only 
a minor part.
202
 
 
Despite this some cardiac surgeons remain reluctant to operate on patients with carotid 
disease and recommend combined or staged carotid endarterectomy in all patients with 
carotid artery disease to reduce the risks of perioperative stroke.  Other centres reserve 
this procedure only for patients with recent neurological symptoms.
203
  Supportive data 
in the form of a randomised controlled trial is lacking for either of these management 
strategies.  The most recent systematic review of case series of carotid endarterectomy 
studies suggested that little or no benefit for stroke prevention appeared to be gained by 
performing staged or synchronous procedures in asymptomatic individuals undergoing 
on pump cardiac surgery.
204
 
 
Carotid angioplasty as an alternative approach to managing carotid disease in these 
patients was originally proposed in 1997 with two published case series of balloon 
deployed carotid stents and a further retrospective series in 2002.
93, 205, 206
  These small 
case series highlighted the fact that although technically feasible neurological 
complications continued to occur both at time of stenting and during cardiac surgery.  
Our centre has performed a staged carotid stenting procedure for significant carotid 
artery stenosis in patients listed for coronary artery bypass since April 1998.  Stenting 
techniques have developed significantly since 1998 with reductions in morbidity and 
mortality.  However, the effect the stenting procedure has on the overall morbidity and 
mortality following coronary artery bypass surgery remains unclear.  We reviewed our 
recent experience of this two staged approach in an attempt to improve outcomes from 
all our stenting procedures. 
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ii) Methods 
 
All patients since 1998 found to have a significant carotid artery stenosis on duplex 
ultrasound criteria during pre assessment for cardiac surgery were referred to the 
combined Vascular Neuroradiology multi disciplinary team.  It should be noted that 
routine carotid duplex ultrasound screening of all patients prior to cardiothoracic 
procedures is not performed by all surgeons at our institution, and therefore not all 
patients with carotid stenosis meeting our criteria for intervention would have been 
offered stenting and be included in this review.  This sample population is therefore a 
non randomised partially selected group which will bias the outcome assessment to a 
degree.  Patients referred to the multidisciplinary team were deemed appropriate for 
carotid intervention if they had a severe carotid stenosis of greater than 80% on the side 
of the dominant hemisphere and a combined stenosis of the carotid arteries of more than 
150%; a recently symptomatic carotid of greater than 70%, or contra lateral occlusion 
and moderate stenosis >50% .  All assessments were performed using the NASCET 
criteria.
26
  These patients then underwent arch angiography to assess the origins of the 
carotid vessels and to confirm the degree of stenosis, additional images to confirm circle 
of Willis anatomy were not routine in pre assessment work up of these patients.  A 
limited number of patients did undergo MRI scanning as part of a separate ongoing 
MRI cerebral perfusion study, but results from these investigations were not used to 
make treatment decisions.
207
  Where treatment was being recommended for a combined 
stenosis of the carotid vessels of greater than 150% the artery supplying the dominant 
hemisphere was preferentially recommended for stenting.  If a vessel was found to have 
been symptomatic within the preceding 6 months, on further detailed questioning, it was 
chosen for stenting.  Since 1998 carotid stenting has been the only management strategy 
used in our institution to treat carotid artery stenosis meeting these criteria.  If patients 
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were unsuitable for stenting a staged or combined carotid endarterectomy was not 
performed as an alternative.    The timing of cardiac surgery following the stenting 
procedure was at the discretion of the cardiac surgeon.  Following the introduction of 
routine use of clopidogrel in carotid stenting it was recommended that this was 
continued for at least 14 days.  Statistical analysis was performed using SPSS 12.01 
software. 
 
Stenting technique 
 
All procedures were performed by an interventional radiologist (Dr T. Cleveland, Prof 
P. Gaines).  During the study period the endovascular technique has evolved to include 
the routine use of dual antiplatelet therapy with aspirin and clopidogrel prior to stent 
insertion as well as the use of filter cerebral protection devices.  The carotid stenting 
technique used in our centre has been previously described in peer reviewed literature.
4
 
Procedures performed in our institution since November 2002 use glycopyrolate 600 
micrograms in place of intra arterial atropine to prevent peri-procedural bradycardia and 
hypotension.  The 8mm or 10mm Monorail Carotid Wallstent (Boston Scientific Corps) 
was used in 90% of these procedures. 
 
Outcome assessment 
 
All patients were assessed prior to treatment, at discharge, and 30 days following the 
procedure by an independent stroke neurologist (Dr M Randall, Dr F. McKevitt, and 
Prof G. Venables).  Outcome events occurring prior to 30 days, because of an 
intervening cardiac procedure were also classified by a neurologist.  Outcome measures 
including all neurological complications occurring within the first 30 days of the 
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procedure and those associated with the cardiac procedure were included in this study.  
Yearly follow up from the date of the procedure has been maintained wherever possible 
with direct clinical assessment, or by telephone interview and review of hospital notes 
and death certification.  Consent for data collection and storage of information on a 
computerised database was obtained from each patient at the time of the procedural 
consent.  This database is registered for audit purposes in accordance with the audit 
procedures of our institution. 
 
Neurological complications 
 
Minor stroke was defined as a new neurological deficit lasting more than 24 hours but 
less than 7 days. Major stroke was defined as a new neurological deficit that persists 
more than 7 days. This classification has then been subdivided at 30 days post event 
into non-disabling stroke, if the Oxford modified handicap score was 0-2, or disabling 
stroke, if the Oxford modified handicap score was equal or greater than 3.
191
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iii) Results 
 
65 patients were referred to the multi disciplinary team for assessment of staged carotid 
stenting prior to coronary revascularisation between April 1998 and July 2005.  52 
patients had significant carotid artery disease according to our intervention criteria that 
was treated prior to cardiac surgery.  The 13 remaining patients were referred back to 
their cardiothoracic surgeon with a recommendation to proceed without carotid 
intervention as they were shown to have combined stenosis of less than 150% at arch 
angiography.  Additional history obtained at the time of stenting revealed that 7.7% 
(4/52) of our patients had transient neurological symptoms within the preceding 6 
months and therefore in 3 cases were treated despite the combined stenosis being less 
than 150%.  All patients were due to undergo cardiac bypass surgery and two patients 
required aortic valve replacement as well.  Patient demographics of the treated patients 
are summarised in table 7. 
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Table 7 Baseline Characteristics of patients undergoing stenting pre CABG 
 
 
 n = 52 
Age (Mean) 68  
Male : Female 45 : 7 
Carotid treated Left : Right 36 : 16 
Delay between Carotid and Cardiac operation. (range) 2 – 60 days 
Combined stenosis (Mean/Median/Range) %  165 / 170 / 105 – 195  
Treated vessel stenosis (Mean/Median/Range) % 83 / 80 / 65-99 
Contra lateral pre occlusive 99% or occluded 100% 20 (38.4%) 
Symptoms within 6 months 4 (7.6%) 
Hypertensive 40 (76.9%) 
Hypercholesterolemia * 47 (90.4%) 
Diabetes 16 (30.7%) 
Smoker (Current or previous) 46 (88.4%) 
Technical  
Carotid Wallstent 47 (90%) 
Protection device used 36 (69.2%) 
Combined Aspirin and Clopidogrel 43 (82.7%) 
 
* Total cholesterol > 5mmol/l 
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30 day follow up was performed in all patients with 94.2% (49/52) undergoing the 
cardiac surgical procedure that had been proposed following stenting.  Our long term 
follow up data ranges from 30 days to 5 years with a mean follow up of 2.1 years.  All 
52 patients remained event free during and immediately following the carotid stenting 
procedure.  Table 8 summarises outcome events from both the stenting and cardiac 
bypass procedure.  At the time of 30 day follow up, excluding events related to any 
cardiac procedure performed within 30 days of stenting, one patient had died.  This 
event occurred at 24 days during sleep at home, no post mortem was performed, and 
heart failure prior to her CABG and valve replacement procedure was the presumed 
cause of death.  This was the only event occurring not related to a cardiac procedure 
occurring with 30 days of stenting.  Two further cardiac deaths occurred prior to the 
cardiac surgery being performed at 56 days, and 59 days respectively.  One patient 
experienced delay to cardiac surgery due to worsening cardiac function, and the other 
suffered a fatal myocardial infarction, at another institution, 3 days prior to his cardiac 
surgery, 59 days following the stenting procedure.    
 
Combined 30 day outcomes for the carotid stenting procedure and cardiac procedure 
include 3 strokes (1 minor, and 2 major non-disabling) all ipsilateral to the stented 
vessel, 2 cardiac deaths and 2 stroke related deaths (one ischaemic and one 
haemorrhagic) occurring in the 30 day post operative period for the cardiac procedure.  
Only one of these procedural strokes occurred at the time of the cardiac operation, this 
patient was unrousable following anaesthetic and eventually died 28 days later.  The one 
minor and 2 major strokes occurred between 24 hours and 48 hours after the bypass 
procedure.  On an intention to treat basis and including all stroke, cardiac death, and 
deaths in those patients awaiting treatment the overall event rate for stroke and all death 
is 19.2% (10/52) with an ipsilateral stroke and stroke death rate of 7.7% (4/52).  The 
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stroke and all cause mortality for patients that underwent both procedures is 14.3% 
(7/49) with ipsilateral stroke and stroke death rate being 8.2% (4/49).
  
Table 8 Outcomes from combined carotid stent and CABG procedures 
 
 
Events within 30 days of 
stenting prior to CABG 
Events greater than 30 days 
post stent prior to CABG 
Peri-operative events within 30 
days of CABG 
Combined total outcome all 
events 
 % (n) 95% CI % (n) 95% CI % (n) 95% CI % (n) 95% CI 
Minor Stroke 0 0 - 5.7 0 0 – 5.7 1.9 (1) 0.3 – 10.1 1.9 (1) 0.3 – 10.1 
Major Stroke 0 0 – 5.7 0 0 – 5.7 3.8 (2) 1.0 – 12.9 3.8 (2) 1.0 – 12.9 
Stroke Death 0 0 – 5.7 0 0 – 5.7 3.8 (2) 1.0 – 12.9 3.8 (2) 1.0 – 12.9 
Other Death 1.9 (1) 0.3 – 10.1 3.8 (2) 1.0 – 12.9 3.8 (2) 1.0 – 12.9 9.6 (5) 4.1 – 20.6 
Stroke and Death 1.9 (1) 0.3 – 10.1 3.8 (2) 1.0 – 12.9 13.5 (7) 6.6 – 25.2 19.2 (10) 10.7 – 31.8 
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iv) Discussion 
 
The benefits of carotid intervention in symptomatic carotid disease are well documented 
and accepted.
26, 27
  The recently published asymptomatic carotid surgery trial has now 
highlighted the benefits that endarterectomy may offer in a selected group of patients 
diagnosed with asymptomatic carotid stenosis.
208
  The place for carotid intervention in 
asymptomatic patients routinely prior to coronary artery bypass grafting and cardiac 
valve replacement remains controversial particularly as it is still unclear what additional 
workload carotid intervention prior to coronary artery bypass surgery would place on 
overstretched vascular services.  The most recent statistics compiled by the Society of 
Cardiothoracic Surgeons of Great Britain and Ireland show that 25,277 CABG 
procedures were performed in the UK in the year 2003.  Limited angiographic data is 
available on the frequency of concurrent carotid disease in those patients undergoing 
CABG so direct estimates of the number of these patients requiring intervention cannot 
be made.  However, it is known that the prevalence of significant carotid disease 
(>50%) in patients with triple vessel coronary disease is approximately 25% 
209
 which 
suggest that up to 6000 procedures may be required per year in the UK were benefit to 
be shown from carotid intervention.  
 
The most robust data set available in this regard is the recently published systematic 
review of case series and trials of endarterectomy and coronary surgery performed by 
Naylor et al.
204, 210
 This work confirmed the historical data in Brener’s paper from 
1987.
200
  They demonstrated that stroke risk is less than 1.8 % in patients with no 
significant stenosis (< 50%) increasing to 5.2% in patients with bilateral carotid disease 
and 11.2% in patients with a unilateral carotid occlusion.  This historical outcome data 
can be compared with studies assessing patients that have undergone combined and 
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staged carotid endarterectomy or stenting.  Published case series and systematic reviews 
report complication rates of stroke and death with combined and staged procedures 
ranging from 2.4% to 17.7%.
211-216
  Naylor’s systematic review suggests that the 30 day 
stroke risk, including both operative procedures, is 5.4% (CI 3.4–7.2) for a combined 
and 3.7% (CI 1.8-5.5) for a staged procedure.
204
  If we are to include stroke and death 
from any cause the respective rates become 9.5% (CI 7.2-11.8) for synchronous and 
6.6% (CI 4.4-8.8) for a staged procedure.
204
 These figures were derived from the 
selected and limited data set available in the literature, and are therefore inherently 
affected by publication bias, but provided little justification for pre-operative carotid 
intervention with endarterectomy in patients with moderate bilateral carotid disease as 
the complication rates for procedures are not statistically different from the natural 
history data available.   
 
The use of carotid angioplasty or stenting as an alternative to carotid endarterectomy 
prior to cardiac surgery has been proposed as a less risky carotid revascularisation 
strategy.  The literature on carotid stenting contains numerous case series where stenting 
is being performed as an alternative to carotid endarterectomy in, “high risk,” patients 
outside of randomised trials.  The recently published SAPPHIRE trial of stenting in 
high risk patients included more than 80% of its patients from those with ischaemic 
heart disease.
179
 The more specific literature highlighting those patients in whom the, 
“high risk,” indication for stenting was imminent cardiac surgery is limited to three 
published case series with a combined patient population of 109 patients.
93, 205, 206
   
 
Outcome events occurred in 8.25% (9/109) of these patients of which 4 were strokes, 
one resulting in death.  The strokes in these reports all occurred in relation to the 
stenting procedure with 6 additional deaths following the cardiac procedure.  Our 
 73 
 
 
combined minor stroke, major stroke and death rate for our study group of 19.2% 
(10/52) on an intention to treat basis is higher than previously documented in the 
literature.  What is not clear from previous literature is whether the 3 deaths that 
occurred prior to the cardiac procedure in our series would have been included in the 
analysis of these previous studies.  The ipsilateral stroke and stroke death rate of 7.7% 
(4/52) compares favourably (Fishers exact p=0.0192) with the previously published 
results of the systematic review for carotid endarterectomy.  However, the event rate of 
11.5% (6/52) for all stroke mortality events, excluding cardiac events not related to the 
procedures, is not statistically comparable with the results of the systematic review for 
carotid endarterectomy (Chi square p=0.64). 
 
Our case series of 52 patients undergoing carotid stenting concurs with previous 
findings from endarterectomy studies prior to cardiac surgery but fails to show any 
significant benefit in prevention of stroke or death when compared to the historical 
untreated data set.  This is despite the fact that no complications occurred around the 
time of stent insertion.  However, a small data set reporting zero event rates means very 
little, and we must remind ourselves that complication rates from stenting could be as 
high as 5.7 %.
217, 218
  It is possible that the carotid procedure by adding delay to the 
bypass procedure in at least 3 of our patients may have contributed to their deaths of 
cardiac cause.   
 
What this dataset fails to tell us is if there is a subset of patients who are more likely to 
benefit from pre operative intervention, and whether we can predict those most likely to 
have complications.  Peri-operative strokes at the time of cardiac surgery may be 
embolic cholesterol particles from manipulation and clamping of the atheramotous 
aorta, air and platelet emboli from bypass or hemodynamic.  The brains inbuilt ability to 
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regulate its cerebral blood flow and perfusion pressure during this period to prevent 
hypo-perfusion and clear away any emboli is key.  However, the brain’s auto regulatory 
function can be significantly impaired if a high grade stenosis has been present for some 
time.
219
  The impact of this reduced reactivity in patients undergoing coronary bypass 
without prior carotid surgery has been proven with pre operative transcranial doppler 
assessment of patients undergoing cardiac surgery.  Those who suffered strokes were 
more likely to have a pre operative low or exhausted cerebrovascular reserve.
220
  It has 
been hypothesised, and subjected to computer simulation,
221
 that some of this risk is due 
to the inability of a hypo-perfused brain to wash out emboli that lodge in the circulation 
and this can contribute to hypo-perfusion and watershed type infarction.
222, 223
  
However, it may be that this cerebrovascular reserve improves in some patients and 
adjusting the timing of the second surgery may have positive impact on outcome in 
these patients.
224
 
 
To prevent peri-operative stroke during CABG we may therefore require routine 
preoperative assessment of the brains ability to regulate its own blood supply and 
maintain perfusion pressure within strict parameters.  Techniques including MRI, 
transcranial doppler, and CT perfusion have been used to evaluate risk in patients with 
high grade carotid disease, and those undergoing carotid endarterectomy and carotid 
stenting.
225, 226
  These techniques have successfully demonstrated that a lower 
cerebrovascular reserve in these patients is more likely to result in an adverse clinical 
outcome at the time of the carotid intervention.
225
 Using one of these methods to 
identify high risk patients and then waiting to see if reserve has recovered my be the 
next step in assessing this process. Our centre is already using MRI scanning and 
diamox reactivity testing to assess the cerebrovascular reserve, and collateral circulation 
via the circle of Willis, in patients undergoing carotid intervention, and this technique 
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could be used in future patients in our centre to highlight the group of patients at higher 
risk for peri-operative hypo-perfusion during the cardiac procedure, thereby allowing 
better targeted carotid intervention at our centre in the future.
207
   
 
What should not be forgotten is that there is a clear need for a randomised controlled 
trial of patients with significant carotid disease undergoing cardiac surgery with no prior 
carotid intervention in comparison to those undergoing either stenting or 
endarterectomy as a staged procedure.  The current practice based on non randomised 
data appears to have very little impact on eventual outcomes, and may result in 
unnecessary procedures in up to 25% of the cardiac surgery population.   However, as 
some cardiac surgeons refuse to perform cardiac bypass procedures unless the carotid 
arteries have been treated a randomised trial seems the only way to answer this 
question.  At present because of the reluctance of the cardiac surgeons the decision 
making process at the multi-disciplinary team meeting is usually biased towards 
intervention without evidence to support it.  We accept that a randomised study will 
require a considerable shift in attitudes away from the present management strategy 
employed in many centres worldwide and may prove problematic in its first stages.  Our 
centres management policy with regard to stenting outside of such a trial is currently 
under review.  The limitations of our non randomised observational study are 
recognised but this data adds to the limited world literature on stenting prior to cardiac 
surgery.  However, with the lack of evidence the continued use of carotid intervention in 
these patients with carotid stenting is difficult to support. 
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4 The Effective Platelet Inhibition in Carotid Artery Stenting 
(EPICAS) study methodology. 
 
Summary of Methods 
 
The study was designed as a prospective evaluation into the clinical relevance of 
variations in an individual patient’s response to the anti-platelet regime of aspirin and 
clopidogrel when undergoing carotid artery stenting using transcranial Doppler-detected 
micro embolic signals as a surrogate marker for possible stroke and transient ischaemic 
attack (TIA) risk after stenting.  The study aim was to determine if variations in the 
level of platelet inhibition obtained from a standardised dosing regimen may be relevant 
in clinical practice.  Transcranial Doppler monitoring of patients undergoing carotid 
stenting was performed before, during, and after the procedure and recorded onto digital 
audiotape (DAT) to allow off line single blind analysis.  Blood samples obtained before 
(when possible) and after clopidogrel administration were used to assess each patient’s 
response to this drug using an ADP dependant platelet function assay.  Blood samples 
were also obtained to assess the inhibition of thromboxane synthesis by aspirin.  Each 
patient underwent follow up six weeks after the procedure having completed the course 
of dual anti-platelet therapy, at which point they were expected to be taking only aspirin 
as antiplatelet therapy.
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i) Study Population 
 
Sequential patients undergoing planned elective carotid artery stenting procedures at the 
Sheffield Teaching Hospitals were approached for participation in this study.  The study 
was designed to make no changes to routine practice currently undertaken in the 
selection of patients suitable to undergo a carotid stenting procedure.  Patients were 
consented for the additional transcranial Doppler recordings and additional blood 
samples to be drawn for the platelet function assessments according to the ethically 
approved protocol.  Selection of the design and manufacturer of the stent and protection 
device used during the procedure remained at the discretion of the individual radiologist 
performing the procedure.  This study was not designed to be an assessment of the 
stenting procedure or technology, but to explore the role of platelet inhibition against 
outcome.  Patients interested in taking part in the study were screened for a suitable 
ipsilateral bone window for monitoring of the middle cerebral artery. 
 
Patients were excluded from enrolment based on the following criteria: 
 
1) Patients undergoing a repeat procedure 
2) Patients already taking dual anti platelet therapy with dipyridamole and 
aspirin. (later modified in view of antiplatelet trials in stroke *) 
3) Patients on anticoagulant therapy. 
4) Patients unable to tolerate clopidogrel or aspirin. 
5) Patients unable to tolerate wearing headband monitoring device. 
6) Patients with a possible cardiac source of emboli e.g. atrial fibrillation, 
mechanical heart valves. 
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* A protocol modification was made towards the end of the study to allow patients on 
aspirin and dipyridamole therapy to be included in the study after the National Institute 
for Clinical Excellence (NICE) technology assessment published in May 2005 
(www.nice.org.uk/TA090) recommended dual antiplatelet therapy with aspirin and 
modified release dipyridamole in all Stroke patients.
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ii) Study Methodology 
 
A full history, general medical examination and baseline neurological examination was 
performed at recruitment in accordance with usual neurological practice.  Clinical 
details were recorded on study data collection proforma (Appendix 1).   
 
 A one hour transcranial Doppler (TCD) ultrasound recording from the ipsilateral 
middle cerebral artery was recorded onto coded digital audio tape (DAT) as detailed in 
the TCD methods section.  All recordings were monitored in real time with the Nicolet 
Companion III Doppler emboli detection software in addition to being stored for 
blinded off line analysis as part of the study protocol.  This was a requirement of the 
ethics submission for all patients and all recordings in the study.  If a significantly high 
embolic load were to be shown occurring at any point, suggesting a high risk of 
imminent stroke, it was expected that the investigators should use this information to 
guide clinical decision making.  Transcranial Doppler had been shown to be a useful 
clinical tool during routine carotid stenting and endarterectomy and to deny access to 
this information should a problem arise was felt to be unethical.
111
  This approach was 
in common with other studies using transcranial Doppler assessment of carotid artery 
stenting at the time.  The benefits of this approach in preventing harm to patients have 
since been published.
113
 
 
All patients were provided with the pre-treatment clopidogrel tablets and either loaded 
with two days 300 mg or given a minimum one week course prior to stenting in line 
with current practice.  Patients entering this study were already receiving aspirin 75mg 
following their initial TIA or Stroke. 
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Immediately prior to, during, and following each stenting procedure further one hour 
recordings from the ipsilateral middle cerebral artery were made onto digital audio tape 
(DAT) for later blinded off line analysis.  Post procedure this was performed for the 
first hour immediately the patient had been transferred to high dependency and therefore 
this recording began 10 minutes after completion of the procedure.  Further blood 
samples as detailed in the protocol were obtained during the procedure from the arterial 
sheath prior to heparin being administered intra operatively and 10 minutes after the 
heparin bolus. 
 
Patients were reviewed at between four and six weeks post stenting in the clinic when a 
post procedure carotid duplex examination of the stent was performed.  In addition to 
the carotid duplex being performed a further TCD recording was obtained from the 
ipsilateral middle cerebral artery to assess what effect stopping clopidogrel at 4 weeks 
post procedure had on embolic signal detection rates.  A planned additional interim visit 
at 7 days post procedure for further blood testing and TCD recording was available for 
any patients willing to travel for this additional examination.  Unfortunately no patients 
volunteered for this examination and this was later removed from the protocol. 
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iii) Transcranial Doppler recording protocol 
 
Standardised recordings were obtained using a commercially available EME Nicolet 
Companion III transcranial Doppler machine with a 2mhz transducer.  Recordings were 
made from the ipsilateral middle cerebral artery, and the transducer was fixed in place 
using the manufacturers commercially available head set.  A sample volume of  2mm, 
sweep speed of 5 seconds and a mean (SD) recording depth of 56 (2) mm was used.  
Recordings were undertaken for 60 minutes at each of the protocol time points.  It was 
recognised that signal loss or a patient’s inability to tolerate the head set may result in 
less than optimal recording times and this was to be adjusted for in the analysis.  
Recordings were made in accordance with the international consensus on TCD 
monitoring.
132
   
 
A randomly allocated numbered tape was used for each recording.  Patient details were 
recorded separately and no formal patient identification or episode number was visible 
on the tape.  The log of patient name and recording episode remained blinded to the tape 
reviewer until the code was broken at the end of the analysis.  Tapes were reviewed 
with at least a three month interval from initial recording following a data integrity 
check at the time of the recording to allow unbiased analysis of the data.   
 
Offline analysis of TCD emboli data. 
 
Raw Doppler signal was analysed by playback through the same transcranial Doppler 
ultrasound equipment for spectral analysis of embolic signals.  Each instance of 
probable embolic signal was assessed against consensus criteria for embolic detection.  
Decibel thresholds of ≥5 dB and ≥3 bB above background were used to classify embolic 
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signals decided on by the sensitivity assessments performed on our machine.  Each 
suspect embolic signal was saved digitally on the TCD machine for re review later and 
confirmation of the classification.  These two threshold levels were then used for 
comparison with the platelet function tests.  One hour of recording required 
approximately 2 hours of offline analysis. 
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iv) Platelet function testing 
 
Platelet function testing was performed at the baseline visit (prior to initiation of 
clopidogrel whenever clinically possible), immediately prior to carotid intervention 
before administration of heparin, 10 minutes after administration of heparin (since 
heparin potentiates ADP-induced platelet aggregation)
227
, 7 days after carotid 
intervention in select patients agree to the additional visit, and at 30 day review.  Unless 
patients had been forced to continue taking clopidogrel for a specified indication this 
time point was between 5 - 7 days after termination of clopidogrel therapy to allow 
sufficient wash out time. 
 
Platelet Aggregation 
 
Platelet aggregation was assessed by whole blood single-platelet counting using hirudin 
anti-coagulated blood (6 ml total) and ADP 0.3-100 µmol/L as an agonist using 
techniques that have been previously described by members of the EPICAS trial 
group.
228
   
 
Hirudin anti coagulant tubes containing 60 μl of Hirudin solution were used to collect 
6mls of whole blood at each time point for platelet analysis.  ADP antagonist solutions 
were prepared to the following stock concentrations 100 μM, 30 μM , 10 μM, 3 μM, 1 
μM, and 0.3 μM and maintained on ice till required.  Seven numbered test tubes were 
prepared and 20 μl of each ADP solution was added to the appropriately numbered tube 
according to the following set up and 20 μl of EDTA 100 mmol stock solution was 
added to tube number 7 as control. 
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  Tube number   ADP Concentration (μM) 
   1    100  
   2    30 
   3    10 
   4    3 
   5    1 
   6    0.3 
   7    EDTA 
 
A magnetic stirrer set at 37 ˚C was used to agitate 480 μl of huiridin anticoagulated 
whole blood with the ADP solutions for 4 minutes.  After 4 minutes 1ml (1000 μl) of 
fixative was added to each tube to stop aggregation.  Residual single platelet counting 
was then undertaken using a Sysmex KX21 haematology analyser.  
 
Dr R. Storey, a member of the EPICAS study group, and supervisor for platelet analysis 
in this study has undertaken extensive studies on the effects of clopidogrel using this 
method to assess platelet aggregation. 
228-230
  This method has been shown to be 
particularly discriminating and reliable for assessing the effects of clopidogrel in an 
individual subject (figure 3).  This assay is not affected by aspirin, which does not 
inhibit ADP-induced aggregation in blood anti-coagulated with a direct thrombin 
inhibitor (such as hirudin) rather than citrate 
231, 232
, so this assay primarily assessed the 
effect of clopidogrel (as well as the potentiating effect of heparin).  These values were 
then used with several classification criteria to select patients as “responders,” “semi 
responders,” or, “non-responders.”  The Sheffield Cardiovascular Research group has 
previously used cut offs for post exposure response classification of <40% aggregation, 
40% – 60 % aggregation and > 60% for this classification when examining the response 
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to clopidogrel in patients undergoing coronary stenting procedures.
233
  Analysis of 
published criteria from other investigators, who have suggested criteria for assessment 
of responder / non responder status using similar techniques, provided a combined 
criterion to improve classification.  These criteria were also applied to our data set 
during analysis and then used in combination to classify individuals as non 
responders.
159, 161, 234-236
 
 
Muller’s group has proposed a classification based on absolute inhibition.159   
 
Absolute Inhibition = (Base line aggregation – Post clopidogrel admin aggregation) 
 
Samara et al 
235
 used the same cut off points as Muller’s group 159 classifying patients 
into responder, non responder and semi responder groups but this classification was 
calculated by using relative platelet inhibition values. 
 
Relative Inhibition = [(pre-treat agg – post-treat agg) / pre-treat agg] x 100 % 
 
Patients have also been classified as normal responders and low responders by 
calculation of the percentage inhibition of baseline aggregation according to the 
following equation as previously described.
234
 
 
% inhibition = (PA baseline – PA after clopidogrel / PA baseline) x 100 
 
The patients were then classified as sub optimal or low response if the inhibition was 
less than 40%.   
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We applied all these criteria to our patients for values generated at 10μM ADP 
aggregation.  Comparison of the demographic and patient characteristics of the three 
groups was undertaken using ANOVA for continuous variables and Chi squared and 
Fisher’s exact test for discrete variables.  Calculations were undertaken using SPSS v 
15.01 for Windows and McKay’s software tool for MSDOS for applying Fisher’s exact 
test to any sized two dimensional contingency table where expected values were less 
than 5 negating the assumptions of the chi squared analysis 
www.discourses.org.uk/statistics/fisher.
237, 238
 
 
 
 
Figure 3 Example of Clopidogrel Dose response.  Effect of Clopidogrel 
Administration on ADP induced platelet aggregation when assessed by whole 
blood single platelet counting in a patient from the EPICAS trial. 
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Plasma sCD40L measurements.  
 
Soluble CD40L released from activated platelets has been used previously to measure 
platelet activation.  Platelet-derived sCD40L has been shown to constitute the majority 
of sCD40L found in circulating plasma.
239
  It has been suggested that sCD40L may play 
an important role in the development of restenosis following arterial intervention and 
future cardiovascular risk has previously been associated with higher circulating levels 
of plasma sCD40L.
240, 241
  The degree of inhibition of platelet activation achieved using 
antiplatelet agents can be related to the levels of circulating SCD40L.
242
  The methods 
we used in the EPICAS study protocol have been previously described by other authors 
investigating patients with cardiac disease undergoing heart bypass.
243, 244
  The 
measurement of sCD40L, at time points through out the procedure, was used as a 
possible indicator of any change in platelet activity in vitro to assess the degree of 
inhibition achieved by clopidogrel. 
 
5 ml blood was collected into a tube containing EDTA and centrifuged at 15,000g for 
10 minutes at 4ºC. The supernatant platelet-poor plasma was removed and stored at -
20ºC prior to determination of plasma sCD40L levels.  Plasma sCD40L levels were 
determined using the commercial available Bender MedSystems high sensitivity Human 
sCD40L ELISA.  Specimen collection into EDTA was undertaken to prevent activation 
of the samples platelets.  These samples are appropriate for the Bender Medisystem 
analysis as detailed in their accompanying instructions for use.  The validity of using 
EDTA samples has been confirmed by other authors.
245, 246
  A spectrophotometer with 
micro plate reader set to 450nm absorbance with 620nm as a reference wavelength was 
used to calculate the concentration of substrate.  Labsystems genesis v3.05 software 
calculated a standard curve from control concentrations and then computed the 
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corresponding sCD40L concentration from the mean absorbance from each patient’s 
paired samples.  Concentrations of sCD40L were assessed for normal Gaussian 
distributions and where appropriate non parametric testing with Wolcoxon methods was 
applied, logarithmic transformation to normalise the data was also applied to allow 
parametric testing to be performed.
247-249
  Results were analysed in comparison with the 
ADP platelet aggregation tests and transcranial Doppler embolic signal counts. 
 
Serum thromboxane B2 measurement 
 
Aspirin exhibits mild antiplatelet activity through inhibition of the cyclo-oxygenase 
(COX-1) pathway causing a reduction in thromboxane A2 (TXA2) synthesis in platelets 
and consequently a reduction in platelet aggregation.  The inhibition of the COX-1 
pathway is rapid, saturable and at low doses of aspirin irreversible.  The effects of 
aspirin variability was not a primary end point for the EPICAS study and therefore 
detailed analysis of thromboxane dependant platelet aggregation, with multiple agonist-
induced platelet aggregation tests was not undertaken in this pilot study.   
 
An alternative assay using the indirect measurement of thromboxane A2 (TXA2) 
production and inhibition was undertaken as a limited assessment of this pathway.  This 
technique has previously been used extensively to characterise the clinical 
pharmacology of aspirin as an antiplatelet agent, and was performed as simplified 
indicator of aspirin effectiveness in our patient population.  Thromboxane A2 has a half 
life of 37 seconds and cannot be measured physiologically.  However, as it decomposes 
into the stable metabolite Thromboxane B2 (TXB2) which can be measured 
physiologically this can be assumed to directly reflect TXA2 production.
250
  The 
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methods have been previously described for plasma and urine samples in patients with 
known cardiovascular and cerebrovascular disease.
251-254
 
 
All our patients were taking aspirin prior to enrolment in the study and therefore pre 
aspirin plasma levels of TXB2 could not be assessed in these patients.  Baseline TXB2 
levels can vary in patients not treated with aspirin between 200 and 600 ng/ml.
255
  It has 
been shown that functional relevance in vivo occurs when the maximum capacity to 
generate thromboxane ex vivo has been inhibited by at least 95%.  Therefore levels of 
less than 10 ng/ml and 30 ng/ml were chosen as levels indicating sufficient suppression 
of the TXA2 pathway in our patients. 
 
A 5 ml sample of whole blood was collected in a plain glass tube incubated at 37ºC for 
60 minutes prior to centrifugation at 2500 G for 10 minutes. The serum was separated 
and stored at -20ºC.  The samples were then analysed using R&D systems, Inc 
Thromboxane B2 (TXB2) antibody mediated immunosorbent assay 
(www.rndsystems.com cat no DE0700).  The assay is based on the competitive binding 
technique in which the TXB2 present in a sample competes with a fixed amount of 
alkaline phosphatase-labeled TXB2 for sites on rabbit polyclonal antibody.   A 
spectrophotometer with micro plate reader set to 405nm absorbance with wavelength 
correction of 570 nm and 590 nm was used to calculate the concentration of substrate.  
Labsystems genesis v3.05 software calculated a standard curve from control 
concentrations and then computed the corresponding TXB2 concentration from the mean 
absorbance from each patient’s paired samples.  
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v) Serum C-reactive protein measurement. 
 
Increased CRP following coronary intervention has been associated with an increased 
risk of restenosis.  The relationship between inhibition of platelet function and CRP 
levels following carotid arterial interventions has not yet been defined by previous 
investigators.  These levels were monitored in the study protocol to see if any 
inflammatory reaction noted during stenting was related to any impact on platelet 
inhibition. 
 
A 5 ml sample of whole blood was collected in a plain glass tube incubated at 37ºC for 
60 minutes prior to centrifugation at 2500g for 10 minutes. The serum was separated 
and stored at -20ºC.  The commercially available Kalon Biological Ltd High Sensitivity 
C-reactive protein (HSCRP) enzyme linked immune assay was used to detect ultra low 
levels of CRP in the patients.  This assay is based on the double antibody sandwich 
format. A spectrophotometer with micro plate reader set to optical densities of 405nm 
absorbance was used to calculate the concentration of substrate.  Labsystems genesis 
v3.05 software calculated a standard curve from control concentrations and then 
computed the corresponding HSCRP concentration (μg/L) from the mean absorbance 
from each patient’s paired samples. 
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vi) Study size calculation. 
 
Previous work by other investigators allowed initial power calculations to be made 
before undertaking this study.  Transcranial Doppler detection of micro embolic signals 
had previously been used to assess the benefits of adding a novel antiplatelet medication 
to low dose aspirin during carotid endovascular intervention. 
114
  This suggested that 
when appropriate platelet inhibition had been achieved with antiplatelet medication the 
number of embolic signals detected in the ipsilateral middle cerebral artery were 
significantly reduced or abolished.
114
  In patients with insufficient platelet inhibition the 
number of embolic signals detected immediately post procedure could be as high as 76 
signals per hour with a mean of 25.  Our study was not investigating the impact of 
clopidogrel or placebo on emboli counts but by assuming that patients who are, “non 
responders,” in our study are equal to patients only taking aspirin this previous data set 
could be used to calculate an initial sample size to demonstrate a statistically significant 
difference between our patient groups.  It had already been shown that between 10 – 
20% of patients may not respond or respond poorly to clopidogrel and this information 
allows us to assume a ratio of 1 in 5 or 1 in 10 for the power calculation of responders 
to non responders in the sample population.
108, 158-161
 
 
Several assumptions were required to perform this calculation: 
 
1) Individual patients will respond variably to the inhibitory effects of the 
antiplatelet agent clopidogrel and can be classified as responders, non 
responders or semi responders. 
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2) This variability directly affects the number of platelet rich embolic particles 
produced after stent insertion and consequently the production of detectable 
micro embolic signals. 
 
3) A good responder will reduce or abolish embolic signal production post stenting.  
In contrast a poor responder will produce a significant number of embolic 
signals as shown in previous trials in patients treated only with Aspirin. 
 
4) Between 10 – 20%  of patients may not respond to clopidogrel.108, 158-161 Ratios 
of 1 in 5 and 1in 10 can be used for the power calculations. 
 
Calculations for sample size determination were performed using the using the open 
access PS power and sample size programme.
256
  The data available from the previous 
investigators studies allowed us to conclude that responders to clopidogrel may produce 
up between 50 to 80% fewer embolic signals than patients who were non responders.  
Non responders were assumed to have a mean embolic signal count of 30 per hour with 
SD of 10.   
 
The α type one error was chosen as 0.05 and the study was powered at 0.80.  The 
difference in the mean emboli counts for the two groups was calculated to be between 
15 or 24 based on a 50% - 80% reduction in counts from 30.  An initial study size of 
between 10 patients and 44 patients was suggested to ensure sufficient power based on 
these preliminary calculations.  An initial assessment point of 25 patients was chosen 
before preliminary review.  External review of the protocol and power calculation was 
undertaken as part of an application for funding to the UK Stroke Association funding.  
Protocol modifications following this review were undertaken Dec 2003. 
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Statistical Analysis 
 
The commercially available statistical analysis packages Microsoft Excel, 
LEADTOOLS Inc SPSS version 15.01 and Graph Pad Software Inc Graph pad Prism 
5.01 were used for data analysis.  The open access McKay analysis tool was also used 
to undertake some Fisher’s exact analysis on r x c contingency tables that failed to 
satisfy requirements for Chi squared analysis with expected values smaller than 5.  The 
methods used for data analysis is discussed in methods of analysis sections in the 
results.
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5 Results of EPICAS Study 
 
i) Platelet function analysis and classification of patients 
 
a) ADP dependant platelet aggregation tests 
 
Standardised definitions to define an individual’s responsiveness to clopidogrel are 
lacking.  Some studies quote clopidogrel resistance based on differences between pre 
and post-treatment platelet reactivity.
161
  Other studies have described it according to 
the degree of inhibition of platelet aggregation values obtained at baseline and after 
treatment.
159
  These studies using arbitrary cut-off values to describe patients as 
clopidogrel resistant may not reflect the true pattern.  It is likely that there is a spectrum 
between patients that have been classified, “resistant,” and those patients who are, 
“super responders.” 
 
It has already been shown that an individual patient’s response to a standard clopidogrel 
loading dose of 300mg followed by 5 days of clopidogrel 75 mg can be highly variable.  
This is easily demonstrated in the EPICAS patient group by comparing baseline 
aggregation with 10 uM ADP solution to post clopidogrel dosing regimes. This is 
illustrated in figure 4.  When represented graphically it appears that before treatment 
most patients have a similar aggregation response to stimulation with 10 uM ADP 
solution but following administration of clopidogrel 3 clear groups of patients can be 
defined.  The first group are those that respond extremely well to the standard regime of 
clopidogrel loading and have post exposure aggregation of less than 40%.  The second 
group of patients have an intermediate level of response and aggregate between 40% 
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and 60 % of their platelets. A final group classified as the, “non-responders,” or, 
“resistant,” patients have post clopidogrel loading aggregation that remains >60%.233 
 
Figure 4 Platelet aggregations before and after clopidogrel loading in the 
EPICAS study immediately prior to carotid stenting.  Results of whole blood single 
platelet counting in response to a 10 uM ADP aggregation stimulus. 
 
Classification of these patients as non-responders, semi responders, and responders  
based on Muller’s criteria as previously described in cardiac stent patients is shown 
graphically in figure 5 and also in the comparison table 9.
159
  Clopidogrel non-
responders are defined by an inhibition of ADP (10 Mol/L) induced platelet aggregation 
that was less than 10% when compared to baseline values after clopidogrel intake, semi-
responders were identified by an inhibition of 10 to 29% and patients with an inhibition 
over 30% were regarded as responders. 
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Figure 5 Effect of clopidogrel on ADP-induced platelet aggregation. Plots of 
individual patient values of maximal aggregation prior to and after clopidogrel 
administration.   Response to 10 μM ADP and classification responder, non-
responder and semi-responder based on absolute inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
Samara et al 
235
 used the same cut off points as Muller’s group 159 classifying patients 
into responder, non responder and semi responder groupings but this classification was 
calculated by using relative platelet inhibition values.  The classification of these 
patients is graphically represented in figure 6.  Using both relative and absolute 
reactivity has been shown to be more accurate at detecting non responders 
233
 and 
comparison of these methods on classification is shown in table 9.
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Figure 6 Effect of clopidogrel on ADP-induced platelet aggregation.  Plots of 
individual patient values of maximal aggregation prior to and after clopidogrel 
administration.   Response to 10 μM ADP and classification as responder, non-
responder and semi-responder based on relative inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
Application of Angiolillo’s technique for classification of platelet responsiveness 234 is 
demonstrated graphically in figure 7 and compared with the other classifications used 
in table 9.  Patients having ≥ 40% inhibition of platelet aggregation 24 h after 
clopidogrel administration were defined as normal responders, whereas those having 
<40% inhibition were classified as low responders. 
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Figure 7 Individual Values of 10μM ADP-induced platelet aggregation before 
and after administration of clopidogrel with normal and low responders classified.  
Mean and SD aggregation values are expressed for each time point. 
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Combining all 4 techniques on our data set makes it possible to identify patients who 
would be classified as non responders in all classifications.  For the purposes of analysis 
patients 4, 10, 13, 20, 22 and 23 have been classified as non responders, patients 1, 7, 
11, 14, 16, 17, 19, 24 and 27 are full responders and the remaining patients have been 
classified as semi responders.  The EPICAS study group therefore had 6 non 
responders, 11 semi responders, and 9 full responders (Chi – Squared 1.462 p = 0.482).  
These results are shown in table 9.  
 
Comparison of clinical characteristics of each of the patient groups is shown in table 
10.  It was expected that the distribution of patients exhibiting each characteristic would 
have been equally distributed between the groups and this was tested using one way 
ANOVA and Fisher’s exact tests for any sized contingency table.  The only statistically 
different variables between the groups were shown to be the initial clinical event (p = 
0.030), a previous history of angina (p = 0.028) and previous history of stroke prior to 
the current index event (p = 0.005).   
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Table 9 Classification of individual patient response to clopidogrel loading 
comparison of 4 classification techniques and classification used for analysis. 
Patient Storey 
233
 Muller Samara Angiolillo EPICAS 
classification  R SR NR R SR NR R SR NR Norm Low 
1 ■   ■   ■   ■  Responder 
2  ■   ■  ■    ■ Semi 
3  ■  ■   ■    ■ Semi 
4   ■   ■   ■  ■ Non 
5  ■  ■   ■   ■  Semi 
6  ■   ■   ■   ■ Semi 
7 ■   ■   ■   ■  Responder 
8  ■  ■   ■   ■  Semi 
9   ■  ■   ■   ■ Semi 
10   ■   ■   ■  ■ Non 
11 ■   ■   ■   ■  Responder 
12  ■  ■   ■    ■ Semi 
13   ■   ■   ■  ■ Non 
14 ■   ■   ■   ■  Responder 
15   ■  ■   ■   ■ Semi 
16 ■   ■   ■   ■  Responder 
17 ■   ■   ■   ■  Responder 
18  ■  ■   ■    ■ Semi 
19 ■   ■   ■   ■  Responder 
20   ■   ■   ■  ■ Non 
21             
22   ■   ■   ■  ■ Non 
23   ■   ■   ■  ■ Non 
24 ■   ■   ■   ■  Responder 
25   ■  ■   ■   ■ Semi 
26 ■     ■  ■   ■ Semi 
27 ■   ■   ■   ■  Responder 
28  ■  ■   ■    ■ Semi 
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Table 10 Patient demographics when classified based on response to 
clopidogrel. 
 
 Non 
Responder 
Semi -
Responder 
Responder p 
      
Number patients in each group 6 11 9 0.482 
      
Mean Age (yrs) 67 72.64 69.56 0.305 
      
Male 5 9 7 0.909 
      
Presentation 
TIA 6 4 2 
0.030 Stroke 0 6 5 
Asymptomatic 0 1 2 
      
Left Carotid treated 3 6 1 0.370 
      
Previous 
medical history 
Angina 0 3 6 0.028 
Prev TIA 1 1 1 0.885 
Prev. Stroke 4 0 0 0.005 
Hypertension 7 10 5 0.721 
Diabetes 0 1 2 0.155 
Hypercholesterolemia 7 10 5 0.721 
Statin 7 11 5 0.260 
      
Smoker 
Current 2 2 1 0.909 
Ex  6 7 4 0.933 
      
Stent 
Carotid Wall Stent 5 7 4 
0.843 Nex Stent 2 2 1 
Other 1 2 1 
Mean Diameter (mm) 8.00 8.09 8.33 0.836 
Mean Length (mm) 30 30 30  
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ib) sCD40L analysis 
 
Statistical Methods 
 
The concentrations of sCD40L from the EPICAS patient population do not conform to a 
normal Gaussian distribution when analysed with the D'Agostino-Pearson test.  
Previous authors have used two methods for analysis of sCD40L data when it is not 
normally distributed.  Both methods were applied to the EPICAS data.  Logarithmic 
transformation of the sCD40L concentrations allowed for statistical analysis with 
student T tests 
241, 247, 257
.  In addition non parametric methods including the Wilcoxon 
signed rank were also applied to the data without the transformation.
249, 258, 259
  
Comparison between sampling points and between patient groups classified on the basis 
of platelet aggregation tests was undertaken.  It was hypothesised that when compared 
to SCD40L levels at enrolment those patients with platelets not adequately inhibited by 
aspirin and clopidogrel would have higher levels of sCD40L.  Individual patient data is 
displayed graphically in (figure 8).   
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Figure 8 Graphs of Individual patient data -1*Log(sCD40L concentration) 
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Results 
 
No clear trends were identified from one time point to the next on graphical 
representation allowing identification of individual at risk patients. A one way ANOVA 
was applied to the data confirming this finding.
259
  No significant difference in the 
means or variances between the 4 time points (F = 0.4049 p = 0.7498) were shown.  
Figure 8 does suggest that there may be a downward trend in sCD40l levels from 2 
hours after the operation to the 30 day follow up period, but this cannot be confirmed 
statistically.  
 
Paired T tests on the log transformed data were undertaken looking for significant 
changes between each of the sampling time points (figure 9).
241, 247
  There was no 
statistically significant difference demonstrated between pre clopidogrel loading and 30 
day post operative sCD40l levels (p = 0.5027), pre clopidogrel loading and peri 
operative samples (p = 0.2620), pre clopidogrel loading and post operative samples (p = 
0.9379), or the perioperative and 2 hour post operative samples (p = 0.0515).  The only 
significant difference was shown between the post operative and 30 day samples (p = 
0.0133) as suggested in figure 9.   
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Figure 9 Dot plot of individual patient results for SCD40L concentrations 
with mean values shown.  Significant differences shown by paired student T test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These outcomes differed slightly when analysed with the paired Wilcoxon method on 
outcomes for the whole dataset with significant differences seen between the peri 
operative and 2 hour post operative periods (p = 0.0003), and the pre clopidogrel 
loading and 2 hour post operative periods (p= 0.020). (figure 10) 
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Figure 10 Comparison of median SCD40L concentrations at each time point 
with paired Wilcoxon test.  Significant differences shown. 
 
 
 
 
 
 
 
 
 
 
 
 
Data was then analysed for changes between the time points based on previous 
classification as responder, non responder or semi responder.  ANOVA and Paired T 
tests comparing sampling time points were undertaken.  This showed no significant 
difference in the means or variances across the 4 time points for non responder (p = 
0.76) semi responder (p = 0.89) and responder (p = 0.99) groups.  For the non 
responders no statistically significant differences were shown between pre operative and 
30 day post operative sCD40l levels (p = 0.41), pre clopidogrel loading and peri 
operative samples (p = 0.39), peri-operative and 2 hour post operative samples (p = 
0.27) or post operative and 30 day samples (p = 0.39).  In the patients fully responsive 
to clopidogrel a similar pattern was seen between pre operative and 30 day post 
operative sCD40l levels (p = 0.94), pre clopidogrel loading and peri operative samples 
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(p = 0.86), peri-operative and 2 hour post operative samples (p = 0.78), and post 
operative and 30 day samples (p = 0.30). 
 
The semi responder group were different with no statistically significant differences 
demonstrated between pre operative and 30 day post operative sCD40l levels (p = 0.79), 
or pre clopidogrel loading and peri operative samples (p = 0.45).  However, changes 
were seen between the peri-operative and 2 hour post operative samples (p = 0.004) and 
the post operative and 30 day samples (p = 0.045) (Figure 11).  In these patients there 
was an increase in the mean level of sCD40L detected at the two hour point in patients 
who were not completely inhibited by clopidogrel.  This transient increase returned to 
baseline values 30 days after the procedure.
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Figure 11 Individual patient data highlighting change between time points for 
patients classified on the basis of platelet aggregation studies.  Paired Student T 
test for significance differences shown. 
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Concentrations of sCD40L are expected to rise when platelets become activated.  They 
have also been shown to increase after being suppressed when clopidogrel is withdrawn.  
Analysis at each of these time points between the three classifications with student’s T 
test and Welch’s correction failed to show any significant difference at any time point 
between responders and semi responders or non responders (Figure 12).
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Figure 12 Time of sampling comparison with responder status for SCD40L 
concentrations.  Comparison between groups by Student T test with Welch 
correction for unequal variance. 
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ii) Transcranial Doppler Emboli counts 
 
Statistical methods 
 
All analysis of transcranial Doppler emboli counts was performed off line by review of 
the coded DAT tapes.  Recordings were performed for one hour at each time point in all 
patients.  Emboli were classified according to the international consensus document 
tailored to our TCD equipment with a cut off of 5dB.
132, 260, 261
  In addition we 
performed analysis based on no decibel cut-off as described by the CARESS 
investigators.
143
  Due to signal degradation including movement of the headset on the 
patient some recordings had been degraded and the full hour was not available for 
analysis.  The distribution of events detected was random throughout the hours 
recording time and therefore adjusted emboli counts were used to represent number of 
emboli per hour in the analysis.  The spatial distribution of the emboli detected 
throughout the recordings have been plotted in figure 13. 
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Figure 13 Temporal distribution of embolic events throughout the hour 
recording period (5dB cut-off). 
 
 
 
 
 
 
 
 
 
 
The data was assessed for normality with the D'Agostino & Pearson normality test.  
Small p values suggest a low probability that the sample comes from a Gaussian 
distribution and in all of the time periods assessed none had emboli counts that match a 
Gaussian distribution (figure 14).  To facilitate analysis of embolisation rates a log 
transformation was performed to reduce the number of outliers and the degree of skew 
and thereby allowing assessment of the results with one way ANOVA and T tests 
performed between the time points.  Patients with emboli counts of zero were given 
nominal counts of 0.3 per hour to assist in the transformation and analysis in line with 
previous practice.
143
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Figure 14 Transcranial Doppler emboli per hour per patient for each time 
period.  D'Agostino & Pearson test for Gaussian distributions shown at each time 
point. 
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Results 
 
A significant difference was seen between the emboli counts at each time point with the 
5dB cut-off (p = 0.035) and when no decibel cut off was used (p=0.043) with ANOVA 
analysis performed across the time points.   
 
Comparison between each of the time points for a cut off of 5dB showed no significant 
difference between pre clopidogrel loading and post clopidogrel loading emboli counts 
although the trend was for a reduction in the mean counts from 3.3 to 2.3 emboli per 
hour (p = 0.24).  No significant differences could be demonstrated between pre loading 
and 30 days post operative (p = 0.84), or post loading and 30 days post operative (p = 
0.89).  Significant changes in emboli counts were seen between the pre clopidogrel 
loading and post operative (p = 0.05), post clopidogrel loading and post operative (p = 
0.03) and post operative and 30 day (p = 0.04) time points. (Figure 15 and Table 12)   
 
Including all emboli in the analysis ignoring a decibel level cut off using the CARESS 
investigators technique yielded similar results except in this analysis no statistically 
significant change was seen between the pre clopidogrel loading and post operative 
counts despite an increase in mean emboli detected from 3.8 to 8.8 per hour between the 
time points (p = 0.08).
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Figure 15 Comparison between time points of emboli counts detected per hour 
for 5dB cut off and no specified dB cut off. Log (Emboli count/hour) normalisation 
of data before analysis with ANOVA and T test performed.  Significant differences 
are shown. 
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Table 12 Comparative Emboli counts per hour from each time period and 
statistical comparison between the groups using paired T tests.   
Significance level  p = < 0.05. 
 
Time 
Emboli count per hour 
Comparison 
T test 
5dB no dB 5 dB no dB  
Median mean SD median mean SD  p p 
          
Pre 
clopidogrel 
loading (1) 
2.0 3.3 5.3 2.0 3.3 5.3 
1 – 2 0.2390 0.2602 
1 – 3 0.0464 0.0759 
Post 
Clopidogrel 
loading (2) 
1.3 2.3 2.4 1.3 2.3 2.4 
2 – 3 0.0287 0.0286 
2 – 4 0.8921 0.2855 
Post 
operative 
(3) 
2.8 8.2 16.5 2.8 8.2 16.5 3 – 4 0.0373 0.0188 
30 days 
post 
operative 
(4) 
1.6 2.4 2.4 1.6 2.4 2.4 4 – 1 0.8411 0.3696 
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iii) Comparison of embolic load with platelet function tests. 
 
Statistical Methods 
 
Embolic signals were analysed as continuous and discrete variables when comparing the 
results of embolic counts with platelet function tests.  Emboli counts at each time point 
were classified according to the patients responder status as previously described.  Prior 
to each analysis the data was assessed for Gaussian distribution with the D'Agostino & 
Pearson test.  Several groups failed to conform to a normal distribution and Logarithmic 
transformation was performed on the emboli count to improve normality and allow 
assessment with parametric techniques.  The data was then analysed with ANOVA and 
T test’s to compare between responders, non responders and semi responders, and 
within the groups at each time point.  This procedure was repeated for patients using the 
5 dB cut off and no decibel cut off to classify emboli.  This analysis was then repeated 
using the methods described by Angiolillo 
234
 to classify platelet reactivity into normal 
and low responsiveness. 
 
Previous studies investigating correlation between platelet function and Doppler 
embolic signals in carotid endarterectomy have split patients into high and low risk 
groups based on the number of embolic signals detected in the first 3 hours post 
operative.   Patients with greater than 25 signals were classified as high risk and those 
less then 25 as low risk.  A similar system of classification for analysis based on emboli 
per hour in the post operative period was used in this analysis.
262
  Fishers exact test 
compared the groups using these methods. 
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A direct correlation analysis was performed comparing percentage platelet inhibition 
with 10 μM ADP solution and embolic counts at each time period to see if this impacted 
on embolic counts in a univariable analysis.  This was performed for adjusted emboli 
counts.  The data was analysed with Spearman’s correlation for non parametric data as 
the results were not normally distributed.
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Results 
 
When the 5 dB cut off for emboli classification was used no statistically significant 
difference was seen at any of the time point for each of the patient response 
classifications.  Analysis between the responder classifications at each time point also 
showed no difference in outcomes.  Immediately post operatively patients classified as 
non responders had a mean emboli count of 9.4 emboli which was not statistically 
different from the semi responders count of 3.5 or the responders count of 13.05 (p = 
0.88).  Within the non responder group there was also no significant difference between 
pre procedure post clopidogrel loading counts and the immediate post procedure values.  
Mean counts increased from 2.6 to 9.4 but this was not statistically significant (p = 
0.32).  Complete results for the 5dB cut off are summarised in table 13 and figures 16 
and 17.  The analysis was repeated using no dB cut off for emboli detection.  The 
results were identical to the 5 dB cut off group and the results are shown in table 14 and 
figures 18 and 19.
  
 
Table 13 Comparison of emboli counts classified with the 5 dB cut off compared between time points.  Log transformation applied to data 
prior to T Test. 
 Emboli count per hour Co
m
p
are 
T test 
Time Non Responders Semi Responders Responders no
n
 
sem
i 
resp
 
 
M
ed
ian
 
M
ean
 
S
D
 
M
ed
ian
 
M
ean
 
S
D
 
M
ed
ian
 
M
ean
 
S
D
 
 p p p 
              
Pre clopidogrel (1) 0.92 1.2 0.78 3.5 3.1 1.81 2.0 4.6 8.40 
1 – 2 0.36 0.18 0.40 
1 – 3 0.09 0.70 0.43 
Post clopidogrel (2) 1.8 2.6 2.3 0.92 2.4 3.0 1.4 2.1 1.9 
2 – 3 0.32 0.09 0.16 
2 – 4 0.79 0.80 0.41 
Post operative (3) 2.2 9.4 17.0 3.1 4.0 2.9 2.9 13 25.7 3 – 4 0.25 0.14 0.40 
30 days post operative (4) 1.6 1.7 1.2 1.7 2.4 2.7 1.5 2.8 2.6 4 – 1 0.48 0.27 0.93 
  
 
 
Table 14 Comparison of emboli counts classified with no dB cut off compared between time points.  Log transformation applied to data 
prior to T Test. 
 Emboli count per hour Co
m
p
are 
T test 
Time Non Responders Semi Responders Responders no
n
 
sem
i 
R
esp
 
 
M
ed
ian
 
M
ean
 
S
D
 
M
ed
ian
 
M
ean
 
S
D
 
M
ed
ian
 
M
ean
 
S
D
 
 p p p 
              
Pre clopidogrel (1) 1.83 1.59 1.09 3.71 3.62 2.12 3.0 5.20 8.20 
1 – 2 0.45 0.26 0.40 
1 – 3 0.23 0.63 0.37 
Post clopidogrel (2) 2.20 3.60 3.59 1.63 2.80 3.26 2.25 2.55 2.12 
2 – 3 0.59 0.11 0.12 
2 – 4 0.24 0.88 0.54 
Post operative (3) 2.50 9.60 17.35 4.17 4.54 3.17 3.84 14.04 25.4 3 – 4 0.14 0.15 0.27 
30 days post operative (4) 0.53 1.38 1.87 2.50 2.84 2.88 1.70 3.31 3.15 4 – 1 0.51 0.34 0.78 
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Figure 16 Emboli count per hour 5 dB cut off compared with ADP mediated 
platelet aggregation classification.  Emboli counts on Y axis on log scale.  
Comparison on transformed data with ANOVA and T tests between 2 groups. 
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Figure 17 Comparison between each classification and each time point 5 dB 
cut off.  Emboli counts plotted on Log scale.  Statistical analysis performed with 
ANOVA on transformed data comparing between groups. 
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Figure 18 Emboli count per hour no dB cut off compared with ADP mediated 
platelet aggregation classification.  Comparison on transformed data between 
groups with ANOVA and t test.  Emboli counts on Y axis plotted on log scale. 
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Figure 19 Comparison between each classification and each time point no dB 
cut off.  Emboli counts plotted on log scale. ANOVA on transformed data 
comparing between groups. 
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The data was then re analysed using Angiolillo’s criteria for classifying platelet 
responsiveness.  At each time point there was no significant difference demonstrated 
between the mean emboli counts of patients classified as having a, “normal,” response 
to clopidogrel and those having a, “low,” response (figure 20).  The post operative 
counts in particular showed no difference with mean and standard deviations of 11.63 
(24.4) for normal responders and 6.20 (10.4) for low responders respectively (p = 
0.683).  Comparison within the group of normal responders showed no statistically 
significant difference in mean emboli counts between the post loading 1.935 (1.78) and 
post operative 11.63 (24.4) time points (p = 0.217).  However, the difference in mean 
emboli count post loading 2.56 (2.79) to post operatively 6.21 (10.4) in the patients who 
were low responders was shown to be significant (p = 0.024) (figure 21). 
 
The analysis was repeated with no decibel cut off for emboli.  Similar results were 
obtained at each time point with no significant difference demonstrated between the 
mean emboli counts of patients classified as having a normal response to clopidogrel 
and those having a low response (figure 22).  Comparison within the group of normal 
responders showed no statistically significant difference in mean emboli counts between 
the post loading 2.50 (1.86) and post operative 12.51 (24.2) time points (p = 0.275).  As 
with the 5dB cut off the difference in mean emboli count post loading 3.17 (3.49) to 
post operatively 6.70 (10.5) in the patients who were low responders was the only 
difference shown to be statistically significant (p = 0.042) (figure 22). 
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Figure 20 Comparison between responders and low responders classified by 
Angiolillo’s method using 5 dB emboli cut-off.  T test performed on transformed 
data.  Emboli count on Y axis plotted on log scale. 
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Figure 21 Comparison between time points within the groups of normal 
responders and low responders classified by Angiolillo’s method for a 5 db cut off.  
Comparison between time points performed on transformed data with ANOVA 
and T test.  Y axis plotted on log scale. 
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Figure 22 Comparison between responders and low responders classified by 
Angiolillo’s method using no dB cut off.  T test performed on transformed data.  
Emboli count on Y axis plotted on log scale. 
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Figure 23 Comparison between time points within the groups of normal 
responders and low responders classified by Angiolillo’s method for no db cut off.  
Comparison between time points performed on transformed data with ANOVA 
and T test.  Y axis plotted on log scale. 
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Patients can also be classified by the number of emboli produced post procedure into 
high and low risk groups for future events as previously described by Naylor’s group.262  
The EPICAS data was subjected to this classification to see if this classification 
reflected the degree of platelet inhibition achieved by the procedure when using 
Angiolillo’s method of classification for low or high responders.  No association using 
fishers exact test was shown between the future risk of recurrent events as classified by 
the emboli counts and the patients response to clopidogrel when assessed in our small 
number of patients (p = 0.63) (figure 24). 
 
Figure 24 Comparison between future risk of stroke based on post operative 
emboli count and response to clopidogrel as assessed by Angiolillo’s method. 
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A direct comparison between embolic signal counts and the percentage of aggregation 
achieved with 10 μM ADP solution using Spearman correlation failed to show any 
significant correlation for all time points assessed (r = 0.0094  (-0.2936 - 0.1134), p = 
0.36).  The results were then separately analysed at each time point and a very weak 
statistical correlation was shown in the post stenting period, but this post hoc analysis 
should be viewed with caution as it is likely to have little clinical significance (figure 
25).  The analysis was then repeated with the sCD40L levels.  No link had previously 
been demonstrated between sCD40L and ADP induced platelet aggregation and it was 
considered possible that plasma levels of sCD40L could be a more accurate reflection of 
platelet activity at each time point, and would therefore correlate more accurately with 
micro embolic signal counts.  Direct comparison of sCD40L plasma levels and the 
number of embolic signals detected at each point was performed with Spearman 
correlation for non parametric data.  These results are shown in figure 26.  A significant 
correlation was shown between the levels of sCD40L detected post operatively and the 
number of micro embolic signals detected on TCD when assessed with spearman 
correlation co-efficient (p = 0.0023).  A line of best fit has been plotted on the figure.  
For clarity the y axis has been plotted on a log scale but the line reflects the original data 
points and therefore plots as a curve.  At no other time point was a correlation seen.
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Figure 25 Correlation between 10 μM ADP induced platelet aggregation and 
embolic signal count per hour (5dB cut off).  Spearman correlation co –efficient.  Y 
axis plotted on log scale. 
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 Figure 26 Correlation between plasma levels of SCD40L and Micro embolic 
signal count (5dB cut off).  Spearman correlation co–efficient. 
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iv) High Sensitivity C Reactive Protein (HSCRP) analysis 
 
Statistical methods 
High sensitivity C reactive protein (HSCRP) samples were collected from the patients 
prior to loading with clopidogrel, immediately prior to the stenting procedure being 
performed and 30 days after stent insertion.  Comparison between time points pre 
clopidogrel loading and post clopidogrel loading were performed with paired student T 
tests on log transformed data. 
 
Analysis was then performed to see if a direct relationship could be observed between 
the emboli count at each time point and the measured level of HSCRP.  This analysis 
was performed with spearman correlation for non Gaussian distributed data.  The results 
have been plotted on log scales for clarity. 
 
Results 
 
Comparing overall levels of HSCRP across the three measured time periods using the 
ANOVA method showed no statistically significant difference in levels between the 
groups (p = 0.98).  Using t tests to compare between two time periods also failed to 
show the expected reduction on inflammation and overall levels of circulating CRP 
when clopidogrel was administered (figure 27). 
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Figure 27  Levels of CRP measured at each individual time point.  Comparison 
on log normalised CRP concentrations with paired T test. 
 
 
 
 
 
 
 
 
 
 
 
 
Directly comparing the number of embolic signals detected using the 5dB cut off at all 
of the time points under consideration with CRP levels failed to show any correlation 
between HSCRP levels and emboli p = 0.13 (figure 28).  When individual time periods 
were analysed no correlation was seen between the pre or post clopidogrel loading time 
periods, but was seen with the 30 day post procedure results.  The correlation was 
statistically significant r = 0.424 (-0.0102 to 0.724), p = 0.05 at this time point and may 
reflect continued inflammatory activity in the stented carotid. 
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Figure 28 Comparison between HSCRP levels and mirco embolic signals 
detected per hour using the 5dB cut off.  Analysis with Spearman correlation. 
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vii) Thromboxane  
 
Serum thromboxane samples were collected from all patients at the time of entry into 
the study, during the operative procedure and post procedure at the 6 week follow up 
visit when clopidogrel had been discontinued.  Thromboxane levels were measured in 
pg/ml by the assay used.  Therefore the 10 ng/ml cut off for insufficient inhibition in our 
patients is equivalent to 10,000 pg/ml for analysis. 
 
A comparison between each of the time periods was undertaken using the Wolcoxon 
signed rank test for non-parametric paired data. 
  
Results 
 
No patient sample was detected that had a level of serum thromboxane level of 10,000 
pg/ml prior to, during or 6 weeks after the procedure.  Assuming the assay to be 
accurate, all of the patients in our small sample are “aspirin responders.”  Applying a 
more stringent cut off used by some authors of 2.2 ng/ml or 2200 pg/ml 
253
 fails to 
indicate that any of the patients tested in our small sample have deficient inhibition of 
thromboxane synthesis. Using these criteria there appeared to be no patients that 
satisfied the previously described cut off’s for reduced responsiveness to aspirin and 
therefore no further comparative analysis with emboli counts could be undertaken. 
 
No statistically significant differences were seen between any of the time points tested 
(figure 28). 
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Figure 28 Plasma thromboxane B2 levels in EPICAS study subjects at each 
time point.  Wilcoxon signed rank test for significance. 
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6 Discussion of EPICAS study results 
 
The primary end point of the EPICAS study compared the rate of transcranial Doppler 
detected micro embolic signals with an individual patient’s responses to the antiplatelet 
agent clopidogrel.  Prior to the study power calculations were undertaken to detect 
differences between patients classified as clopidogrel resistant and clopidogrel 
responsive.  Patients classified as clopidogrel resistant were assumed to be likely to 
have a higher frequency of embolic events.  The calculations were based on figures in 
published studies and abstracts that had used a similar technique for investigating novel 
antiplatelet agents during carotid endarterectomy and stenting procedures.
114, 263-266
   
 
The primary assessment of the patient’s platelet response showed the expected pattern 
of intra individual variation.  Patient classification based on their response to 
clopidogrel was in the expected distribution in our patients when using accepted criteria 
in the published literature to determine whether a patient was a responder or non 
responder.  When classification was compared across each patient it was seen on several 
occasions that the classifications disagreed.  This variation in classification could have 
impacted on the outcomes when comparing directly the number of emboli produced at 
each time point, and therefore multiple analyses using the previously described 
techniques were employed in our analysis.  In this study and the majority of 
classification schemes failed to demonstrate a significant cause and effect in univariate 
analysis between clopidogrel responsiveness and post operative rates of micro emboli.   
 
The immediate message from this result is that clopidogrel responsiveness and 
clopidogrel variability have no effect on the clinically silent embolic signals seen during 
carotid stenting procedures.  This may be because the changes we expected to see in the 
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numbers of clinically silent emboli are not clinically significant, although this seems 
unlikely in view of the outcomes now available from the CARESS study as previously 
discussed.  It is more likely that the effects of variation in clopidogrel responsiveness 
are so small that even using a more prevalent surrogate end point such as Doppler 
detected emboli to increase detection sensitivity fails to show the difference in the small 
number of patients we have studied.  It could also be hypothesised that even a poor 
clopidogrel response is sufficient to reduce cerebral emboli and provide a protective 
effect.  What is clear is that the assessment of clopidogrel responsiveness in vitro has no 
clear standardised measurement and this makes the interpretation of study outcomes 
difficult. 
 
The carotid stenting procedure is a complex process with multiple variables interacting 
to determine clinical outcomes and with patient physiology, operator experience, 
operator technique, and pre operative pharmacology all contributing.  Within this 
complex process single variable analysis, unless it is a highly significant variable, is 
likely to have limitations and fail to detect minor trends.  However, univariate analysis 
is an accepted technique when screening for significant variables for later multivariate 
analysis and in most cases when a variable is not shown to be positive in univariate 
assessment it has little or no effect on a multivariate model.  It is therefore unlikely that 
a significant effect has been missed.  In this study the limitation is likely to be that 
complete Clopidogrel resistance occurs at a relatively low frequency, and therefore its 
effects, if any are present, are likely to be small and undetectable at a clinically relevant 
rate based on the small numbers of patients studied due to these complex interactions. 
 
Embolic signals were used in this study as surrogates for clinical endpoints and should 
have increased the likelihood of an index event occurring because they are often found 
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at higher frequencies than clinically detectable events during carotid stenting 
procedures.  Previous publications have also suggested that the majority of the surrogate 
embolic signals detected by TCD are likely to have little clinical relevance as most 
would be incapable of causing a clinically relevant stroke event.  Without applying 
additional prediction algorithms to separate out the embolic signals that could signify a 
higher clinical risk from those of lower risk it is possible that a significant trend in this 
trial data may remain hidden.  The lack of significance found in the analysis may be 
shown as a stronger trend if larger trials using clinical endpoints of stroke and TIA were 
undertaken because only clinically significant embolic events would be included. 
 
Patient selection should not have adversely affected the outcome from this study.  All 
the patients recruited into the EPICAS study were representative of the population of 
patients undergoing intervention at the Sheffield teaching hospitals in 2003 – 2005.  The 
majority of the patients studied underwent stenting for symptomatic carotid stenosis and 
asymptomatic procedures were only performed on a few patients awaiting coronary 
artery bypass surgery.  The three asymptomatic patients included in the analysis could 
have had a minimal effect on the outcome.  Other publications have suggested that  
asymptomatic patients have more stable plaque morphology than patients with a 
recently symptomatic stenosis.
267, 268
  This could theoretically have affected the number 
of emboli detected post procedure by increasing the number of cholesterol based emboli 
released from symptomatic lesions.  Symptomatic plaques have also been shown to 
generate higher baseline levels of platelet activation than asymptomatic plaques which 
could have increased the pre clopidogrel platelet responsiveness making any reduction 
detectable with clopidogrel use more significant in the symptomatic patients.
269
  In the 
EPICAS study population this effect is likely to be undetectable and not impact 
significantly on the outcomes as only 3 patients were involved and are spread across the 
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classifications. Future studies should consider this in the planning stage and the patient 
population should be limited to a purely symptomatic cohort. 
 
The EPICAS study design was intentionally observational not interventional.  The aim 
was to investigate the true clinical impact of reduced clopidogrel responsiveness in real 
life situations, and therefore no prescription was placed on an operator’s stenting 
technique, choice of stent or peri procedural protection device use.  Stents used were of 
open or closed design as the operator felt appropriate for the individual patient being 
treated.  Each design of stent has differing physical properties that make one more 
suitable than another for certain anatomical and operator variables.  However, because 
they have a different anatomical profile and are constructed from different materials 
they may have a variable thrombo-embolic potential that could impact on emboli 
produced.  The majority of stents used in routine practice by Sheffield vascular 
radiologists are of the closed stent design.  In most situations it is possible for the 
operator to decide on the appropriate design and manufacturer of stent prior to the 
procedure which would have allowed us to limit the design of stent used in the trial.  
However, because unexpected procedural issues can mean that a different design is 
eventually inserted than what was planned, and it was therefore decided not to be 
prescriptive in this pilot study and determine the impact of clopidogrel resistance most 
reflective of real practice.   
 
Recent authors have now confirmed that to some degree differences in clinical outcome 
may be related to stent design,
71
  and therefore this may have had an impact on the 
embolic counts in the post operative period in our patients.  The differing stent designs 
were distributed evenly between the three classifications of platelet response in our 
patients, and so the impact of this effect is likely to have been minimised in our dataset. 
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If a convincing effect of clopidogrel resistance had been demonstrated in the EPICAS 
study the effect of stent design would have warranted more detailed assessment in 
future larger cohorts, and prescription of a single design of stent for the procedure when 
carrying out follow on studies. 
 
The variability in response to clopidogrel in patients recruited in the EPICAS study 
closely resembles that expected distribution described by previous authors.  Combing 
classification systems used by previous authors to obtain an overall classification of 
responsiveness enabled us to be certain that patients we classified as non responsive 
were those that would have been classified non responders in all previous studies 
undertaken in patients undergoing cardiac procedures, despite variation between the 
analytical techniques.  This classified 6 (22.2%) patients as non responders and is at the 
level expected for the higher estimates used in the original power calculation.  This is 
also comparable with rates published by previous authors.
108, 158-161
   
 
The creation of a semi responder group created a more clear definition between patients 
who definitely responded to clopidogrel and those that had little or no response.  Direct 
comparison between the non responders and, “good,” or, ”normal,” responders becomes 
more meaningful as they now represent the extremes of the antiplatelet response 
spectrum.  If differences in emboli counts cannot be demonstrated at the extremes of 
clopidogrel effectiveness then any hypothetical effect that this may have on clinical 
outcomes is unlikely to be significant.  We were also interested in, “semi 
responsiveness,” or a partial response as this hypothetical group has never been fully 
assessed by any of the previous authors working in the field of cardiology. 
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The transcranial Doppler detected end points used in the EPICAS study should have 
been more sensitive to minor effects in the semi responder group of patients that would 
have not been detectable in the clinical endpoints used previously in the cardiac 
patients.  The techniques used in the EPICAS study should have allowed study of this 
group of patients and to classify more accurately if they respond in a manner closer to 
patients in the non responder or responder groups.  This analysis was not powered for in 
the initial calculations, and therefore any secondary analysis made based on this data 
needs to be treated with caution.  Our complete analysis of this group has shown that no 
significant differences or trends were shown and we must therefore assume that either 
the study was under powered to detect any change or there was no true effect. 
 
Whilst it is likely that the correct finding is that no true effect exists is should be 
remembered that the assumptions to power the study were based on previous authors 
published work.  The mean embolic count of non responders had to be assumed to be 
close to those seen in patients who were previously treated solely with aspirin.  It was 
also assumed that full responders would abolish any embolic events in a similar manner 
to the other agents studied previously assuming clopidogrel to be equally effective.  It is 
clear from the results from the EPICAS study that this effect has not been seen in the 
patients we have studied.  In our small number of patients no clear and repeatable 
differences between the responders and non responders could be demonstrated, although 
some interesting trends have been uncovered that may warrant future study. 
 
Clear benefits of the addition of Clopidogrel to the antiplatelet regimes of patients 
undergoing stenting have been demonstrated based on clinical outcomes and are clearly 
documented in our analysis of our database data and in the literature to date.
9
   The 
effects of clopidogrel on the number of embolic signals detected by the transcranial 
 146 
 
Doppler over and above single agent antiplatelet regimes is not in question.
143
  It is 
therefore assumed that the findings in this study are most likely to reflect the fact that 
the original assumptions leading to the hypothesis are incorrect.  Therefore, differences 
in the level of clopidogrel inhibition between patients are not as clearly defined, and 
therefore emboli detection in such a small number of patients is unlikely to detect any 
significant variation.  To attempt to perform a post hoc power calculations using 
adjusted assumptions based on these results is only likely to reflect what has already 
been determined by the primary analysis.
270
  Further critical analysis is required to 
identify any flaws in the methodology and any sub group analysis that raises questions 
for future study. 
 
If each stage of the experiment is reviewed in turn then a couple of modifications to the 
protocol could improve future studies.  The majority of the transcranial Doppler 
recordings were of good quality and detection of embolic events using the two proposed 
criteria was easily undertaken.  Degradation of some sections of the recordings and 
patient intolerance to the head band device limited the true length of recordings on 
occasions to less than the full hour.  To make comparison of emboli counts meaningful 
between the groups it was necessary to express the figures as events per hour, and this 
introduces assumptions into the experiment that are difficult to adjust for in post hoc 
analysis which could conceivably influence the outcome.  The first assumption was that 
embolic events, if they are going to occur, do so at a constant rate throughout the time 
period under analysis and in a truly random manner.  Therefore, if a segment of 
recording was damaged, lost, or unusable at the beginning of the time period under 
analysis it would be the same as losing a similar section at the end of the recording.  
Therefore, consequent adjustments for rates can be made in a linear fashion. This 
assumption was made after assessing the timing of emboli and their distribution 
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throughout the recordings undertaken.  It is conceivable that this assumption is wrong as 
clinically relevant embolic events have been shown to be more common closer to the 
time of immediate stent deployment when compared to those occurring 24 hours 
later.
271
  The second linked assumption is that patients who have no emboli detected in 
the useable recording will continue to have no emboli detected should a full untainted 
hour recording have occurred.  To a degree this was overcome by assuming a nominally 
low embolic rate of 0.3 emboli / hour for all emboli free recordings to allow for log 
transformation of non parametric data in analysis, but it is not perfect.
143
 
 
Recordings were reviewed blinded to the patient data to reduce bias on the assessment 
and each embolic event selected from the original DAT tape recording was stored 
digitally and re-reviewed on one further occasion before being formally included as a 
positively detected event.  This technique was chosen to increase the reliability of the 
classification of each event and such sequential double reading even by a single 
observer when comparing against a check list of characteristics does in part limit 
selection bias.
272
  The technique is however limited as it depends on a single observer, 
ideally the analysis would have had a second observer but in this pilot study timing and 
budgetary constraints prevented this.  A single observer is more likely to underestimate 
events and when assessing other radiological interventions single observers have 
previously been shown to have lower sensitivity and specificity scores than dual 
observers either reading together or independently.
272
 
 
Two cut off points for true embolic events were used in analysis to ensure that the 
results of this study were comparable with previous work in carotid endarterectomy and 
stenting.  The 5 dB cut off was used as the lowest level that the software could reliable 
detect embolic signals with 100 % agreement with the observer and is in line with the 
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consensus criteria suggesting the use of the lowest most accurate level for an individual 
machine is used this was chosen for the analysis.  The CARESS investigators have also 
published since the EPICAS study began.  In this analysis they did not define decibel 
threshold above baseline as long as the observers were convinced of a true embolic 
event it could be included
143
 and therefore this analysis was also performed on the 
EPICAS data after a protocol amendment.  No embolic signal was detected in our 
cohort at less than 3.6 dB above the background that could be classified with certainty 
as embolic.  It is now becoming clear that the threshold at which emboli can be reliably 
detected is part of a spectrum and is highly dependant on the observer and background 
noise and it is likely this has limited agreement on dB cut off values previously.  In 
some cases 7dB has been taken as the ideal level above background that can be relied 
upon, but newer research has suggested it may be as high as 14 dB or as low as 3dB in 
some situations.
260
  Our dual cut off analysis hopefully ensures that any possible 
statistically links between clopidogrel effect and emboli in the EPICAS study would 
have been detected and subjected to more detailed scrutiny. 
 
The overall trends in the numbers of embolic detected at each time point matched that 
expected in patients undergoing carotid stent insertion.  A minor non significant 
reduction in mean emboli counts was seen after loading patients with clopidogrel pre 
procedure.  In a small number of patients a statistical significance was not to be 
expected but the trend is in line with the reduction in emboli seen in the CARESS study 
where clopidogrel was shown to reduce embolic events in patients awaiting carotid 
endarterectomy.  At both decibel cut-offs a statistically significant increase in the 
number of embolic events occurred in the first hours recording immediately post 
stenting.  This was to be expected, as the stenting procedure leaves the exposed metallic 
stent to act as a platelet stimulant as well as damaged carotid plaque material and 
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endothelial lining which also have the capacity to produce thrombo-embolic material 
without effecting platelet activation.  Trials using clopidogrel in patients undergoing 
carotid endarterectomy confirm that clopidogrel use reduces but does not entirely block 
emboli production.  It is possible that this is a reflection the production of cholesterol 
emboli rather than a failure of platelet inhibition.
266
  The embolic potential of the carotid 
returns to baseline 30 days after the procedure as expected when the patients were 
reassessed without clopidogrel.  At this time point implanted stents have begun to 
develop an endothelial covering reducing an effect on platelet activation.
166
  Stents have 
a very low embolic potential when assessed with delayed follow up confirming what 
has been seen in histological specimens of removed stents.
142
 
 
The primary end point for the study was the impact of variable clopidogrel response on 
the number of embolic signals detected in the immediate post operative period.  We 
undertook recordings during the stenting procedure for off line analysis in case an intra 
operative event occurred but there were no plans to analyse peri procedure data in the 
initial protocol.  These results have not been included in this study as the small effects 
attributable to the variable antiplatelet effects of clopidogrel were felt to be undetectable 
during the stenting procedure itself because of, “noise,” in the signal generated by wire 
manipulation, stent deployment and contrast injections.
97, 137, 273
  The type of protection 
system used has been shown to impact on the particle number and size which would 
have made an assessment during this period even more complex.
139, 274
  The majority of 
solid particles generated during the stenting procedure are athero embolic plaque 
material rather than thrombo embolic platelet rich thrombus therefore clopidogrel would 
have had no affect on their production during the peri operative period and therefore it 
could acceptably be excluded from the analysis.  It has been argued by previous authors 
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that conventional TCD monitoring during this period has little impact on predicting 
outcome and no clinical benefit.
275
 
 
The post operative analysis is the most clinically relevant period when the exposed 
metallic stent acts as a significant stimulus to platelet activation, and therefore the 
greatest benefit of the antiplatelet agents should have been seen at this time and analysis 
was focussed on comparing with pre operative levels.
276
  This analysis in the EPICAS 
study failed to show a statistical link between the increased number of embolic signals 
already seen at this time period and the degree of clopidogrel inhibition.   
 
When the 5 dB cut off was applied to the embolic signal detection a non significant 
trend to increased rates of emboli post operatively was seen in the non responder group 
with mean rates increasing from 2.6 to 9.4 emboli per hour (p = 0.09).  However, a 
similar non significant increase in mean emboli rates was seen in the responder group 
2.1 to 13 emboli per hour.  Comparison across the post operative time period also failed 
to show a statistically higher embolic rate in the non responder group when compared to 
full responsive patients.  The premise of the study was therefore not confirmed with the 
data obtained.  Subset and post hoc analysis has revealed some trends that may be 
worthy of further discussion. 
 
Post hoc analysis of the patient in the non responder group with the highest 
embolisation rate revealed immediately post stenting new onset visual symptoms 
occurred.  This patient also had a continued high embolisation rate on TCD detectable 
after the EPICAS analysis period had completed.  This had required IV Dextran 40 as 
an additional antiplatelet agent to terminate his symptoms as previously described and 
permitted in the protocol on review of the automated emboli counter for the first post 
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operative hour analysis.
111, 113, 264
  The IV dextran therapy was continued for 48 hours, 
but this patient later suffered a stroke when the Dextran infusion was terminated and he 
was discharged home.  The platelet function tests for this patient after analysis suggest 
he had a degree of, “clopidogrel resistance,” and therefore terminating the dextran 
therapy in effect left this patient on single agent aspirin therapy with highly active 
platelets post operatively.  Despite no significant effect on emboli in the cohort of non 
responders being demonstrated by the EPICAS study it must be remembered that for 
this individual patient the effect was devastating.   
 
Individual patient notes review was also performed on the patient group classified as 
responders.  One of these individuals had very high emboli rates detected post 
procedure and the following morning he became blind ipsilateral to the carotid that had 
been treated.  He was later shown to have had a cholesterol embolic event with a 
cholesterol embolus seen on fundoscopy in the retinal artery causing an acute pan 
ischemic retina.  Clearly in this case the clopidogrel status of this patient had no effect 
on the rate of cholesterol embolisation that contributed to the high post operative emboli 
counts and the clinical visual loss.  However, very high embolic rates resulted in a 
clinical event supporting the link between detection of a high embolic load and the 
likelihood of poor clinical outcome.   
 
Review of the post stenting angiographic run prior to removal of the sheath showed 
radio opaque material apparently being squeezed between the mesh of the stent making 
pure cholesterol plaque embolisation the likely cause of the increased embolic signals in 
this patient, although exact aetiology could not be determined from the TCD analysis 
alone.
277, 278
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Of note the Nexstent that was used in this patient has now been subject to an FDA 
withdrawal due to problems with its delivery system detaching and causing strokes.  
Excluding this count from the dataset, assuming all emboli were cholesterol emboli in 
nature, had no effect on the statistical significance comparing non responders to 
responders in the first post operative hour analysis (p = 0.59). 
 
It has been previously argued that platelet inhibition by clopidogrel is a continuum of 
variation, patients should more correctly be classified as patients with platelets that have 
a high and low responsiveness to stimulation with ADP and the attenuation of this 
response by clopidogrel can then be classified into normal and low response.  Patients 
should then only be classified into normal responders or low responders on this basis.  
This analysis when undertaken in the EPICAS patients suggested that a link between a 
low response to clopidogrel and high embolic rates post stenting in comparison to the 
pre operative state.  However, this post hoc re–analysis of the data was not provided for 
or powered for at the outset of the trial and it is therefore difficult to draw any clinically 
significant conclusions from this, but it acts as a pointer for future studies, looking at 
this method of classification compared with clinical not Doppler endpoints. 
 
Soluble CD40 ligand (SCD40L) was chosen in the EPICAS study as an alternative 
indicator of platelet function and activation because platelet derived sCD40L makes up 
the majority of the sCD40L detectable in circulating plasma.  Activation of platelets 
releases sCD40L and therefore it has been hypothesised that low levels of sCD40L 
indicate that an acceptable degree of platelet inhibition had been achieved.  We 
expected to see an increase in detectable levels of sCD40L in the post operative period 
and for these levels to be higher in patients classified by the other methods as non 
responders.  This was not shown in the EPICAS patients, and may reflect the small 
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numbers of patients in each classification, as changes were seen between time points in 
the larger semi responder group.  However, as sCD40L is released by platelets when 
they are activated plasma levels may be more reflective of global platelet activation as a 
whole explaining the correlation seen between sCD40L plasma levels and emboli 
counts in the post operative period.  This assumption only confirms using different 
techniques what is already known on the subject of platelet activation and transcranial 
Doppler detected emboli that when platelets become activated, the number of detectable 
micro embolic signals increases.  As a result this cannot be used as evidence that failure 
to inhibit platelet activation with clopidogrel also increases embolic signals. 
 
After stent insertion a number of inflammatory processes occur within the stented 
vessel, carotid plaque and vessel wall that are likely to impact on the number of micro 
embolic signals detected in the immediate and late stenting periods.  Raised plasma 
levels of CRP have been shown to be associated with histological features consistent 
with plaque instability and these unstable plaques may pose a higher stenting risk.
279
   
Platelet activation triggers inflammatory cascades that clopidogrel and other platelet 
agents may have some impact on by reducing platelet activation, but it is unlikely that 
they will have an effect on the inflammatory status of the plaques.  Even when adequate 
platelet inhibition is achieved by suppressing SCD40L release no clear impact on high 
sensitivity CRP has been shown.
249
  In contrast with clopidogrel, statins have been 
shown to have a significant effect on the inflammation within the carotid plaque, and all 
patients in the EPICAS study were taking statins at the time of stenting.  CRP was 
measured in these patients before clopidogrel loading, after loading and at the 30 day 
follow up period.  This failed to show any statistical link between CRP and emboli 
counts in the pre and post clopidogrel loading groups.  The weak but significant 
correlation shown between the CRP level and emboli count in the 30 day post operative 
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period could have been predicted from what is already known.  We already know that 
any patient with ongoing active inflammation is pro-thrombotic, and we would 
therefore have expected these patients to produce more emboli.  It is possible that the 
persistently raised CRP indicates a continuing inflammatory process in the recently 
disrupted plaque and endothelium that has failed to heal, and therefore could directly 
explain the higher emboli count.  Even though it is likely that this is the case, the raised 
CRP and emboli counts alone are insufficient evidence to make such a direct 
assumption without additional histological evidence of an in plaque inflammatory 
infiltrate which is not available in stented patients.  It has been suggested that the 
inflammatory response seen in other vessels is not as significant in the carotid artery 
and may explain the minimal changes seen in the EPICAS data.
280
 
 
The assessment of Aspirin resistance and its effect on carotid emboli was not one of the 
primary goals of the EPICAS study and therefore multiple platelet function assays 
assessing this pathway were not undertaken.  Plasma thromboxane levels were chosen 
as a simple indicator of the global effect of aspirin in an individual patient by its ability 
to inhibit thromboxane dependant pathways of platelet aggregation.  Using the 
diagnostic cut-offs for aspirin resistance previously described no patients in our cohort 
were felt to have laboratory evidence of reduced responsiveness to aspirin.  However, 
this does not correlate with population estimates of up to 20% resistance and brings the 
validity of this data set into question.  Using different point of care testing methods to 
those used in EPICAS another group has shown clopidogrel resistance may occur in 
around 20% of patients with no significant detectable aspirin resistance in patients 
undergoing a selection of stenting procedures.
281
  Whilst this is not validation of our 
methods it is reassuring that similar patterns of platelet function have been seen in other 
groups of patients studied.  With no differences between patients to allow classification 
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into responder and non responder groups for aspirin further analysis of the impact of 
aspirin therapy on outcomes was not feasible. 
 
The EPICAS study is the first study to have attempted to address the issues of 
clopidogrel resistance using several definitions of non responsiveness during carotid 
artery stenting procedures.  It has shown that the methods chosen were valid, as it has 
confirmed that the pattern of distribution of clopidogrel responsiveness shown in 
previous groups of patients was also present in this cohort, and the rise in sCD40L 
levels confirmed that platelet activation was occurring post stenting.  We were also able 
to show a significant increase in emboli rates post procedure was detected as expected. 
 
What the study failed to demonstrate with any certainty was how variation in 
clopidogrel resistance impacts on individual emboli rates.   The clinical impact of very 
high emboli rates post procedure and the significant stroke risk attached to these high 
rates confirmed in previous studies has been confirmed by the EPICAS patient group. 
282, 283
   High embolic rates are clearly a marker of instability in the arteriovascular 
system and it is possible that the addition of clopidogrel to aspirin in the majority of 
patients does not abolished emboli entirely but instead modifies the rate of embolisation 
to below a threshold rate at which clinically detectable events are more likely to occur.  
A shift to focusing attention on monitoring all patients in the post stenting period 
aiming to maintaining emboli rates of less than 10 per hour may be clinically more 
relevant for future study.  A similar analysis in patients undergoing carotid 
endarterectomy has been performed showing an increase in platelet response to ADP 
stimulation and clinical risk if patients had more than 25 emboli in a 3 hour post 
operative period.
262
  We applied some of this reasoning to our data and this post hoc 
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analysis is shown in figure 24, but because the study was not powered to detect this sort 
of a difference it is not surprising that no change was seen.   
 
It is therefore only sensible to conclude that if an effect of clopidogrel response does 
exist it is likely to be too small to detect with our current methods and is more than 
likely to be of little clinical significance. 
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7 Critique of the EPICAS study methods and design.  
 
i) Problems encountered and solutions. 
 
The study was designed based on previous work performed in the Sheffield Vascular 
Institute, Neurosciences division and Sheffield Academic Cardiology unit as described 
in the methods section.  The individual elements of the study had robust methodology 
demonstrated previously but the combination in this small pilot study had been untried 
in this institution and to our knowledge not previously published by any other group.  
Similar studies have since been published in patients undergoing carotid 
endarterectomy.
266
 
 
Performing this pilot study in a small number of patients has highlighted some issues 
with the methodology employed and also helped to focus future studies.  The 
transcranial Doppler recordings were performed in the majority of the patients studied 
to a relatively high standard.  One hour of recording was obtained at the lowest power 
settings achievable for that bone window, and the majority of the recording was useable 
in most patients.  However, problems were noted with some of the recordings being less 
than the full hour.  Patients often complained that towards the end of the hour recording 
that the head band holding the probe in place would become uncomfortable and when 
adjusting the position they could accidentally move the probe during recording.  It is 
now evident that the number of TCD recordings could have been reduced to obtain 
similar outcomes and therefore the length of the recordings could have been extended to 
one and half hours each, with the first hour of useful recording used for analysis.  The 
recordings made before clopidogrel loading and during the procedure may have 
increased patient fatigue with the study process and have not been shown to add any 
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useful data in our analysis.  A significant number of embolic events have also been seen 
to occur at 48 hours post stenting  on both MRI 
284
 and TCD 
133
  studies and therefore an 
additional recording 24 to 48 hours after the procedure may detect changes not seen in 
the first hour post procedure as platelet micro aggregates may have delayed  formation.  
Focussing on pre procedure, one hour post procedure 24 hours post procedure and 30 
days post procedure recordings would probably have been more effective in producing 
stable outcome measures. 
 
The methods used to assess aspirin response in the study can also be criticised as there 
were no clear internal controls.  All the patients in the study were taking aspirin 
following their stroke event, and many of these patients had been taking the medication 
for a considerable time prior to that for other indications.  It might have been worth 
while performing a baseline battery of antiplatelet tests to investigate the aspirin 
pathway at entry into the study before clopidogrel loading occurred to more accurately 
classify these patients degree of aspirin responsiveness.  This was not in the original 
protocol as the study was designed to look in a univariate fashion at the clopidogrel 
pathway, but might be appropriate in future studies.  From our data it is not clear if the 
patient with the very high embolic count in the non responder group was also aspirin 
resistant.  The failure of the combination of drugs may be what makes the difference to 
outcomes but could not be tested with the results obtained from these patients. 
 
Surrogate endpoints always have drawbacks and are easily criticised for being non 
specific for clinically relevant events during carotid intervention, especially when used 
on their own.  Other studies have looked at MRI based endpoints as indicators of 
clinical damage, and have shown significantly higher numbers of post procedure lesions 
in one of the patient groups when comparing protection methods.
285
  However, it is 
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likely a proportion of these lesions have no clinical significance as most have been 
shown to disappear 48 – 72 hours later.286  This raises the issue of using surrogate end 
points in any of these studies.  To improve on the sensitivities’ of these surrogates it 
would have been useful to have performed both TCD and MRI studies in our patients. 
 
ii)  Future work 
 
We have shown that it is unlikely that any significant effect of clopidogrel variability 
can demonstrated in such small numbers of patients and future studies will need larger 
numbers of patients.  It might be worth repeating this study with larger numbers of 
patients splitting the patients into the low or normal responder groups and looking for a 
cut off level of embolic signals of greater than 10 per hour to indicate future high risk.   
 
The benefits of additional antiplatelet agents in patients who fail to respond optimally 
are still under investigation by other groups.  It may be worth repeating the experiment 
in larger numbers of patients selecting out the suboptimal responders and randomising 
them to additional therapy, including the intravenous agents to assess in more detail the 
impact this may have on outcome.  The intravenous GPIIB/IIIA inhibitor,
  
eptifibatide 
has been used in one study in over 400 cases, and only 1 intracranial bleed was shown 
to have occurred, which was later felt to be secondary to cerebral hyperperfusion, 
suggesting this may be a relatively safe medication to consider.
287
  The intravenous 
agents are limited by their length of use and an alternative approach may be to look at 
the triple combination of Aspirin, Clopidogrel and Dipyridamole that has been 
suggested in a review of antiplatelet therapies previously.
288
  Safety data for short term 
use of this combination has already been obtained from a trial in acute stroke using this 
combination.
289
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8 Summary : Can we optimise carotid intervention 
further ? 
 
Ensuring safety for patients during the procedure is the over riding priority in any 
intervention.  This thesis attempted to identify ways in which that risk could be reduced.  
Selecting patients with low risk is clearly preferable but not possible in real clinical 
situations.  What we have been able to show in patients stented in Sheffield is the 
different risk of adverse outcome in those patients who present with retinal events and 
cerebral events, allowing patients to be appropriately informed.  Patients undergoing 
stenting prior to coronary bypass may derive little stroke prevention benefit based on 
the patients selected for this procedure so far.  This issue clearly warrants a randomised 
trial, and patients need to be aware that the benefits of the procedure are not a clear as 
had been previously reported and should make their decision to proceed on that basis.  
 
The current optimised therapy for carotid stenting is clearly superior to the historical 
regimes and the stenting procedure is safer now than at any point in its development. 
The individual elements that make up this optimised therapy have a minor role to play 
on their own, but the combined effect on 30 day outcomes is significant.  The long term 
durability of the procedure will have to be proven by the randomised trials but the 
Sheffield cohort analysis provides supportive evidence over a 5 year period of stent 
durability. 
 
The EPICAS study tried to improve on safety by critically assessing one aspect of the 
optimised treatment regime in an attempt to optimise it further.  It failed in its primary 
outcome measure to convincingly demonstrate any impact of minor variations in an 
individual’s response to clopidogrel therapy.  This finding is in line with trials 
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undertaken in patients undergoing carotid endarterectomy that have investigated 
different components of this procedure, and attempted to optimise the intervention using 
antiplatelet agents, patch materials, and procedural transcranial Doppler monitoring.  
The successful developments are published with statistically significant reductions in 
clinical or Doppler detected micro embolic signal events and these developments 
gradually become part of the recommended procedural technique.  However, the post 
operative complication rates for carotid endarterectomy when subjected to randomised 
trials appear to be very similar to the original NASCET and ECST trials of between 6 
and 8 %.  The complication rates for 30 day any stroke or death in the recent carotid 
intervention trials EVA 3S (3.9%), SPACE  (6.84%) and GALA (4.5%) when 
scrutinised suggest no clear developments in procedural safety with time and this may 
suggest that this is the inherently lowest risk for carotid interventions that can be 
achieved.
170, 173, 290
   
 
One explanation for this is that the limit of technical developments has been reached.  It 
may be impossible to make significant further impact on outcomes that will lower 
complication rates below 4% for any form of carotid intervention in symptomatic 
patients.  This could be because having had a recently symptomatic stenosis delineates a 
group of patients that are, “high risk,” for any procedure that is undertaken on them.  
The experimentation with technical adaptations and monitoring has only served to focus 
the attention of these operators on undertaking as technically perfect a procedure as 
possible.
266
  The dominant factor contributing to the risk that still remains is the, 
“symptomatic,” status of the patient.  This is likely to be an independent risk factor for 
complications and has been suggested when reviewing stenting procedures performed in 
centres where stenting asymptomatic carotid arteries are routine in the same way as 
symptomatic procedures.
291
  The characteristics of the lesion itself will also 
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independently affect outcome and cannot be modified prior to the procedure, and in 
symptomatic patients these lesions are typically more ulcerated and unstable.
292
  The 
combination of these risk factors is now likely to make up a significant degree of the 
hazard ratio apportioned to each procedure in the multivariate analysis and may explain 
why minor adaptations to technique have limited impact on the clinical outcome. 
291
   
 
It is inconceivable that further adaptations to the techniques of carotid stenting and 
carotid endarterectomy are not going to be proposed and tested but it is likely that they 
will have little or no real significant impact on clinical outcomes.  We have probably 
reached the lowest achievable complication rates for both procedures as the procedure 
itself is inherently risky no matter what adaptations are undertaken to the operative 
technique.
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Appendix 1 
Patient Identification Record 
EPICAS study 
 
Patient name:   _____________________________________________ 
Patient unit number:  __________________ 
Date of birth:   __________________ 
Age:    _____ 
Sex    M / F 
 
 
Trial number allocation  
 
Event type  Amaurosis fugax / TIA / Minor Stroke / Major Stroke / CABG 
 
Angio date ______________  Stenosis L ______ R _______ 
 
Previous Medical History     Drug History 
    Yes No 
 
Angina   □ □  Aspirin _______________ 
IHD    □ □  Dipyridamole _______________ 
MI    □ □  Clopidogrel _______________ 
Previous TIA   □ □  Warfarin _______________ 
Previous Stroke  □ □  Statin  _______________ 
Hypertension   □ □  ACE inhibitor _______________ 
Diabetes   □ □  AII blocker _______________ 
Hypercholesterolemia  □ □  β blocker _______________ 
Renal failure   □ □  Ca2+ blocker _______________ 
Peripheral Vasc Disease □ □  Diruretic _______________ 
Smoker   □ □  Nitrate  _______________ 
Ex smoker   □ □    
       Other meds. _______________ 
         _______________ 
Screening Doppler   □ □    _______________ 
         _______________ 
 
Aspirin randomisation number  or Aspirin dose _______________ 
 
Clopidogrel   Batch number 1 _____________ Exp Date _______ 
   Batch number 2 _____________ Exp Date _______ 
 
Date of pre assessment: __________________ 
Date of procedure:  __________________ 
Date of 1
st
 follow up:  __________________ 
Date of second follow up: __________________ 
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Stenting procedure information 
 
Carotid    Left / Right 
 
Make of stent used   _________________________ 
 
Length of stent used   _________________________ 
 
Diameter of stent used  _________________________  
 
Embolic protection device used _________________________ 
 
 
Blood and urine samples taken 
(check box or enter result when samples obtained) 
 
 PRE 
ASSESSMENT 
MORNING OF 
PROC 
STENT 
PRIOR TO 
HEPARIN 
STENT 
POST 
HEPARIN 
1 HR 7-14 
DAYS 
6 
WEEKS 
Full blood 
count  
 
       
Platelet 
aggregation 
test (6ml 
hirudin) 
       
Serum 
thromboxane 
(clotted sample) 
       
CRP 
(clotted sample) 
       
Plasma 
SCD40L 
(5ml EDTA) 
       
 
 Morning of Procedure Morning after Procedure 
Urine Thromboxane   
 
Doppler recordings made 
 
(see separate key to identify numbered tapes relevant to this recording) 
 
Pre assessment   □ 
Prior to procedure (<12 hrs)  □  Time  ____________ 
During procedure   □  Time  ____________ 
Post procedure (<2 hrs)  □  Time  ____________ 
7 – 14 days    □   
6 weeks    □ 
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Doppler recording details 
Entry recording 
 
Date       Depth  
Tape code number     Sample volume 
Tape start time     Power 
Vessel recorded     Duration 
 
 
Pre procedure recording 
 
Date       Depth  
Tape code number     Sample volume 
Tape start time     Power 
Vessel recorded     Duration 
 
Procedure recording 
 
Date       Depth  
Tape code number     Sample volume 
Tape start time     Power 
Vessel recorded     Duration 
 
Post procedure (2 hours) recording 
 
Date       Depth  
Tape code number     Sample volume 
Tape start time     Power 
Vessel recorded     Duration 
 
7 – 14 days recording 
 
Date       Depth  
Tape code number     Sample volume 
Tape start time     Power 
Vessel recorded     Duration 
 
6 weeks recording 
 
Date       Depth  
Tape code number     Sample volume 
Tape start time     Power 
Vessel recorded     Duration 
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Visit Details 
 
Pre procedure 
 
Medication changes since last visit:  _________________________________ 
 
      _________________________________ 
 
 
Clinical events since last visit:  _________________________________ 
 
      _________________________________ 
 
 
7 – 14 days post procedure 
 
Medication changes since last visit:  _________________________________ 
 
      _________________________________ 
 
 
Clinical events since last visit:  _________________________________ 
 
      _________________________________ 
 
 
6 weeks post procedure 
 
Medication changes since last visit:  _________________________________ 
 
      _________________________________ 
 
 
Clinical events since last visit:  _________________________________ 
 
      _________________________________ 
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Adverse events record 
 
 
1) 
 
Date of event:  ___________________________________________________ 
 
Time of event:  ___________________________________________________ 
 
Type of event:  ___________________________________________________ 
 
   ___________________________________________________ 
 
Outcome:  ___________________________________________________ 
 
 
 
2) 
 
Date of event:  ___________________________________________________ 
 
Time of event:  ___________________________________________________ 
 
Type of event:  ___________________________________________________ 
 
   ___________________________________________________ 
 
Outcome:  ___________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genetic sub study 
 
 
      Yes   No 
 
Patient enrolled in genetic sub study    □    □ 
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10 Publications and presentations arising from this thesis at time of 
submission. 
 
Chapter 2 Published in Circulation : Cardiovascular Interventions 2010 3:50-56 
The long term results of carotid artery stents to manage symptomatic 
carotid artery stenosis and factors that affect outcome. 
 
Abbreviated form published as lecture notes  
Symptomatic Carotid Stents with 1700 patient years follow up – How 
can we reduce risk? 
  Book Chapter Charring Cross Vascular meeting 2008 
 
Chapter 3 Published in Stroke 2006 37:435-9  
Is there any benefit from staged carotid and coronary revascularisation 
using carotid stents?  A single centre experience highlights the need for a 
randomised controlled trial.   
Plus responses to letters to the editor x3 
 
EPICAS Presented in poster presentation at Association British Neurologists 
meeting  Bournemouth  May 2010  
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